Changes in thrombin activatable fibrinolysis inhibitor and its role in normal pregnancy and pre-eclampsia by Huq, FY
	CHANGES IN THROMBIN 
ACTIVATABLE FIBRINOLYSIS 
INHIBITOR AND ITS ROLE IN 
NORMAL PREGNANCY AND 
PRE-ECLAMPSIA 
 
 
BY  
 
FARAH YASMINE HUQ BMedSci  BMBS MRCS 
 
A thesis submitted in the fulfilment for the degree of Doctor of Medicine (MD) 
 
 
 
University College London 
April 2017
	 2 
DECLARATION: 
	
	
	
	
	
	
	
	
I declare that the work presented in this thesis is my own and has not been 
submitted to another university. 
 
 
 
 
 
 
 
Signature: 
Date: 1st April 2017 
Name: Farah Yasmine Huq 
	
	 3 
	
 
 
ACKNOWLEDGEMENTS: 
 
 
I would like to offer my deepest thanks to my supervisors Miss Rezan Abdul-
Kadir and Professor Edward Tuddenham for their unerring patience, wisdom 
and kindness.   
This thesis would not have been possible without the patients who generously 
gave up their time to participate in these studies, I would like to express my 
gratitude and wish the all the best with their new babies and their future 
endeavours. 
My sincere gratitude must also go to the staff of the Haemophilia Centre at the 
Royal Free Hospital, especially Anne Riddell.  Equally, many thanks to Mr 
Whitlow and his team at Colchester hospital for all of their help. 
 
 
Finally, for Matthew and Oscar. 
 
 
	 4 
TABLE OF CONTENT 
 
TITLE  
DECLARATION  
ACKNOWLEDGEMENTS 
TABLE OF CONTENTS 
LIST OF TABLES AND FIGURES 
 
Chapter 1: Introduction to MD thesis 
1.1 Introduction 
1.2 Study aims and objectives 
1.3 Thesis layout 
 
Chapter 2: Literature Review 
2.0 Overview of Haemostasis 
2.1 Coagulation 
  2.1.1 Extrinsic Pathway 
  2.1.2 Intrinsic Pathway 
  2.1.3 Final Common Pathway 
  2.1.4 Regulation of coagulation 
2.2 Fibrinolysis 
 2.3 Haemostasis in normal pregnancy 
   2.3.1 Changes in procoagulants 
   2.3.2 Changes in anticoagulants 
   2.3.3 Fibrinolysis 
   2.3.4 Thrombin Generation 
   2.3.5 Placental Haemostasis 
   2.3.6 Platelets 
 2.4 Thrombin activatable fibrinolysis inhibitor 
   2.4.1 Discovery 
   2.4.2 Synthesis of TAFI 
   2.4.3 TAFI activation 
   2.4.4 Physiological roles of TAFI 
    2.4.4.1 The attenuation of fibrinolysis 
    2.4.4.2 The role of TAFI in inflammation 
   2.4.5 Instability of TAFI 
   2.4.6 TAFI inhibitors 
   2.4.7 Pathophysiology of TAFI 
   2.4.8 TAFI in Pregnancy 
    2.4.8.1 TAFI in normal pregnancy 
    2.4.8.2 TAFI in pre eclampsia  
    2.4.8.3 TAFI in recurrent miscarriage and implantation failure 
  2.5 Pre eclampsia 
    2.5.1 Definition 
     2.5.1.a Definition of severe pre eclampsia 
     2.5.1.b Early and late pre eclampsia 
    2.5.2 Maternal morbidity and mortality 
    2.5.3 Risk Factors 
     2.5.3.a Parity and parternity 
     2.5.3.b Maternal age 
	 5 
     2.5.3.c Ethnicity 
     2.5.3.d Medical co-morbidities 
     2.5.3.e Increased placental mass 
     2.5.3.f Obesity 
     2.5.3.g Assisted conception 
    2.5.4 Cardiovascular risk after pre eclampsia 
    2.5.5 Clinical features 
     2.5.5.a Signs and symptoms 
    2.5.6 Pathogenisis of pre eclampsia 
     2.5.6.a Role of the placenta 
     2.5.6.b Vascular development of the placenta 
     2.5.6.c Altered angiogenic balance 
     2.5.6.d Placental ischaemia and hypoxia 
     2.5.6.e Maternal endothelial dysfunction 
     2.5.6.f Haemodynamic changes 
     2.5.6.g Immune changes 
     2.5.6.h Hepatic, renal and cerebral changes 
    2.5.7 Current screening methods for pre eclampsia 
     2.5.7.a Maternal history 
     2.5.7.b Blood pressure 
     2.5.7.c Uterine artery dopplers 
     2.5.7.d Biomarkers 
    2.5.8 Prevention of pre eclampsia 
    2.5.9 Haemostasis in pre eclampsia 
     2.5.9.a Haemostasis in the systemic circulation 
     2.5.9.b Fibrinolysis in pre eclampsia 
     2.5.9.c Uteroplacental circulation 
     
 Chapter 3: Laboratory Method 
  3.0 TAFI antigen and activity assays 
  3.1 Immunological assays 
  3.2 Enzymological assays 
  3.3 Functional assays 
  3.4 Laboratory method for the studies in this thesis 
   3.4.1 TAFI Activity (TAFI Actichrome ®) 
   3.4.2 TAFI Antigen concentration (ELISA) 
   3.4.3 Clot Lysis time 
 
 Chapter 4: Changes in Thrombin activatable fibrinolysis inhibitor in normal  
pregnancy 
  4.1 Introduction 
  4.2 Method 
   4.2.1 Study design 
   4.2.2 Sample size 
   4.2.3 Inclusion and exclusion criteria 
   4.2.4 Data collection 
   4.2.5 Blood collection 
   4.2.6 Laboratory method 
   4.2.7 Statistics 
   
	 6 
4.3 Results 
   4.3.1 Population and demographic data 
   4.3.2 Changes in TAFI Ag, TAFIa and CLT with gestation  
   4.3.3 Reference ranges for TAFI in normal pregnancy 
   4.3.4 CLT in the presence of Buffer and PTCI 
  4.4 Discussion 
 
Chapter 5: Thrombin activatable fibrinolysis inhibitor in pre eclampsia 
 5.1 Introduction 
 5.2 Method 
  5.2.1 Study design 
  5.2.2 Inclusion and exclusion criteria 
  5.2.3 Data collection 
  5.2.4 Blood collection 
  5.2.5 Laboratory method 
  5.2.6 Statistical analysis 
 5.3 Results 
  5.3.1 Demographic data 
5.3.2 Changes in mean levels of TAFI Ag, TAFIa and CLT in pre 
eclampsia 
  5.3.3 Comparison of TAFI in normal pregnancy and pre eclampsia 
  5.3.4 CLT in the presence of buffer and PTCI 
  5.3.5 Correlation between TAFI Ag, TAFIa and CLT in pre eclampsia 
 5.4 Discussion 
 
Chapter 6: Overall conclusions  
 6.1 Overall conclusions 
 6.2 Suggestions for future research 
 
 
Appendix 1: Study Ethical approval 
 
REFERENCES 
 
 
  
 
	 7 
LIST OF TABLES AND FIGURES: 
 
TABLES: 
1. Studies of changes in TAFI Ag and TAFIa in normal pregnancy and Pre-
eclampsia 
2. American College of Obstetrics and Gynecology Criteria for severe pre 
eclampsia 
3. Medical conditions associated with pre eclampsia 
4. Materials	required	for	TAFI	antigen	and	activity	levels	and	Clot	lysis	time	analysis 
5. Number of samples analysed in each trimester of normal pregnancy 
6. Distribution of age, parity, booking weight and blood pressure in normal 
pregnancy 
7. a) Changes in TAFI Ag, TAFIa and CLT throughout normal pregnancy 
b) Statistical significance of changes in the mean values of TAFI Ag, TAFIa 
and CLT in normal pregnancy 
8. Reference intervals of TAFI Ag and TAFIa during each trimester of pregnancy 
9. Reference ranges of TAFI Ag and TAFIa in normal pregnancy 
10. Contribution of TAFI to fibrinolysis assessed by the the difference between CLT 
in the presence of buffer and PTCI 
11. Correlation of TAFI Ag and TAFIa with CLT in each trimester of pregnancy 
12. Number of women with pre eclampsia recruited in each trimester 
13. Distribution of age, parity, booking weight and blood pressure in pre eclampsia 
14. a) Changes in mean TAFI Ag, TAFIa and CLT throughout pregnancy 
complicated by PET 
b) Statistical significance of changes in the mean values of TAFI Ag, TAFIa 
and CLT in pre eclampsia 
15. Comparison of mean TAFI Ag, TAFIa and CLT in normal pregnancy and pre 
eclampsia 
16. Contribution of TAFI to fibrinolysis assessed by the the difference between CLT 
in the presence of buffer and PTCI in pre eclampsia 
17. Correlation between TAFI Ag and TAFIa with CLT in pre eclampsia 
	 8 
FIGURES: 
1. The coagulation cascade 
2. The fibrinolytic pathway 
3. The role of TAFI in fibrinolysis 
4. Changes in mean TAFI Ag levels throughout normal pregnancy 
5. Changes in mean TAFIa levels throughout normal pregnancy 
6. Changes in mean CLT throughout normal pregnancy 
7. Changes in TAFI Ag levels with gestation 
8. Changes in TAFIa levels with gestation 
9. Distribution of TAFIa in each trimester of normal pregnancy 
10. Distribution of TAFI Ag in each trimester of normal pregnancy 
11. Distribution of CLT in each trimester of normal pregnancy 
12. The distribution of TAFa in the first trimester 
13. The distribution of TAFa in the second trimester 
14. The distribution of TAFa in the third trimester 
15. The distribution of TAFI Ag in the first trimester 
16. The distribution of TAFI Ag in the second trimester 
17. The distribution of TAFI Ag in the third trimester 
18. a) Correlation between TAFI Ag and CLT in the first trimester 
b) Correlation between TAFIa and CLT in the first trimester 
19. a) Correlation between TAFI Ag and CLT in the second trimester 
b) Correlation between TAFIa and CLT in the second trimester	
20 a) Correlation between TAFI Ag and CLT in the third trimester 
       b) Correlation between TAFIa and CLT in the third trimester 
21. The distribution of TAFI Ag in the second and third trimesters in PET 
22.. The distribution of TAFIa in the second and third trimesters in PET 
23. . The distribution of CLT in the second and third trimesters in PET 
24. a) Mean TAFI Ag levels throughout pregnancy complicated by PET 
b) Mean TAFIa levels throughout preganacy complicated by PET 
c) Mean CLT throughout pregnancy complicated by PET  
 25. Correlation between TAFI Ag and CLT in the third trimester in pre  
eclampsia 
 26. Correlation between TAFIa and CLT in the third trimester in pre  
eclampsia 
 
	 9 
  
 
 
 
 
Chapter 1 
 
INTRODUCTION TO MD THESIS
	 10 
The Activity of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in 
pregnancy affected by Pre-Eclampsia  
 
1.1 Introduction 
Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently described glycoprotein 
that inhibits fibrinolysis (Bajzar, Manuel et al. 1995).  It can be converted to its active 
form, TAFIa, by proteolytic cleavage by the thrombin/thrombomodulin complex.  
TAFIa inhibits fibrinolysis by removing carboxyterminal residues from partially 
degraded fibrin and decreasing plasminogen binding on the surface of fibrin (Bajzar, 
Manuel et al. 1995; Redlitz, Tan et al. 1995; Bajzar, Morser et al. 1996).  TAFI appears 
to play an important part in the delicate balance between coagulation and fibrinolysis, 
but its role in pathology requires further elucidation.  It seems likely that the activity of 
TAFI is altered in various thrombotic and bleeding disorders.  Increased levels of TAFI 
antigen have been reported in patients with symptomatic coronary artery disease 
(Silveira, Schatteman et al. 2000) and as a risk factor for deep vein thrombosis (van 
Tilburg, Rosendaal et al. 2000).  Decreased TAFI activity has been observed in acute 
promyelocytic leukaemia (Meijers, Oudijk et al. 2000) and disseminated intravascular 
coagulation (Watanabe, Wada et al. 2001).   
 
In normal pregnancy there are increased levels of procoagulation factors, enhanced 
thrombin generation and impaired fibrinolysis (Bremme, Ostlund et al. 1992; 
Comeglio, Fedi et al. 1996).  Since thrombin generation is increased during pregnancy, 
TAFI may contribute to the decreased fibrinolytic state. 
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Pre-eclampsia is a complication of pregnancy induced by impaired placental circulation 
and is associated with haemostatic disturbances commonly observed as the activation 
of coagulation and the impairment of fibrinolysis (Perry and Martin 1992; Gilabert, 
Estelles et al. 1995; Schjetlein, Haugen et al. 1997; Sheppard and Bonnar 1999).  This 
leads to the hypothesis that TAFI is involved in the regulation of fibrinolysis in women 
with these complications of pregnancy.      
 
Several investigators have studied TAFI antigen levels during pregnancy (Chetaille, 
Alessi et al. 2000; Chabloz, Reber et al. 2001; Antovic, Rafik Hamad et al. 2002; 
Alacacioglu, Ozcan et al. 2004; Mousa, Downey et al. 2004) and produced conflicting 
findings.  Chetaille et al found no significant difference in antigen levels between 
pregnant women and age matched controls, although the study was limited by a small 
sample size (n=12) (Chetaille, Alessi et al. 2000).  Subsequent larger studies found that 
TAFI antigen levels increased with gestation (Chabloz, Reber et al. 2001; Mousa, 
Downey et al. 2004).  Two previous studies have investigated the TAFI antigen levels 
in pre-eclampsia (Antovic, Rafik Hamad et al. 2002; Alacacioglu, Ozcan et al. 2004), 
with one including pregnancies affected by intrauterine growth retardation (IUGR) 
(Alacacioglu, Ozcan et al. 2004).  The two studies produced conflicting results:  
Antovic et al (Antovic, Rafik Hamad et al. 2002) found lower levels of TAFI antigen 
in pre-eclamptic women, whereas Alacacioglu et al (Alacacioglu, Ozcan et al. 2004) 
did not find a statistically significant difference.  None of the above studies have 
examined the levels of activated TAFI (TAFIa).    Watanabe et al is the only study in 
the literature that looked at the changes in the concentration of plasma TAFI molecules 
that are present and functional after activation by thrombin-thrombomodulin complex 
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(TAFI activity) during pregnancy (Watanabe, Minakami et al. 2004).  They reported 
higher TAFI activity in pregnant women when compared with non-pregnant women.   
   
The following thesis aims to investigate if and how TAFI levels change during normal 
pregnancy.  This will provide a reference range for TAFI in uncomplicated pregnancy, 
allowing comparison of the changes in the activity of TAFI in plasma during 
pregnancies complicated by pre-eclampsia or IUGR contributes to a better 
understanding of the pathophysiology of these conditions.  TAFI may have a future role 
in the screening and monitoring of these conditions.   
 
1.2 Study Objectives and Aims: 
 
• To determine the nature of changes in TAFI antigen and activity levels 
during normal pregnancy; 
 
• To determine pregnancy specific reference intervals for TAFI Ag and 
TAFIa 
 
• To determine if TAFI antigen or TAFI activity levels correlate with clot 
lysis time; 
 
• To determine if women with pre-eclampsia have altered TAFI antigen and 
activity levels compared with normal pregnant controls and if so, does this 
contribute to impaired fibrinolysis  
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1.3 Thesis layout 
The second chapter of the thesis begins with a brief overview of haemostasis and how it 
is affected in normal pregnancy.  The latter parts of chapter 2 provide a background about 
TAFI, including its role in haemostasis and the pathophysiology of various disease states.  
The final section deals with the current understanding of the pathophysiology of PET and 
changes in haemostasis in the disease. 
The third chapter provides details of the current methods available to assess TAFI levels 
and its effects.  The laboratory methods used in the studies forming the basis of this thesis 
are elucidated in this chapter.   
Chapters 4 details a study of changes in TAFI in normal pregnancy and chapter 5 
compares TAFI levels in PET to the reference range for normal pregnancy defined in 
chapter 4. 
The last chapter of the thesis summarises the findings of the thesis and explains their 
importance with suggestions for further research. 
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Chapter 2 
LITERATURE REVIEW
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2.1: An overview of normal haemostasis 
A brief revision of the coagulation cascade is essential to understand the haemostatic 
changes in pregnancy.  The cascade is a three-part system (constituting of the intrinsic, 
extrinsic and final common pathway) of interlinked positive feedback loops that act to 
form a stable blood clot.  Blood remains fluid because: (i) coagulation proteins circulate 
in their inactive form; (ii) unlike the sub-endothelium the endothelium is devoid of 
thrombogenic Tissue Factor (TF) or collagen and finally (iii) the brisk velocity of flow 
removes any activated proteins to be metabolised in the liver.   
 
2.1 Coagulation 
2.1.1Extrinsic Pathway: 
The primary stimulus for the initiation phase of the extrinsic pathway is the exposure 
of the sub-endothelium subsequent to vessel damage.  This causes the release of tissue 
factor (TF), which then associates with FVIIa to form a complex of FVIIa-TF.  Together 
with calcium and the negatively charged phospholipid surface, FVIIa-TF forms the 
extrinsic FXase.  
 
2.1.2 Intrinsic Pathway: 
Exposure of the sub-endothelial surface stimulates circulating factor XIIa to cleave and 
activate its substrates Prekallekrein and Factor XI into Kallekrein and Factor XIa.  
Positive feedback occurs as Kallekrein activates neighbouring FXII molecules.  
Kallekrein and FXIa become anchored to the sub-endothelium by kininogen.  Factor 
XIa’s serine protease activity cleaves the anchoring kininogen, making FXIa soluble 
enabling it to activate FIX into FIXa.   
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Simultaneously, the small amount of thrombin generated by the extrinsic pathway 
promotes the activation of platelets and factors V, VIII, and XI into FVa, FVIIIa and 
FXIa respectively (Lawson, Kalafatis et al. 1994; Butenas, van 't Veer et al. 1997).  In 
a similar manner to FVII, FVIII forms the intrinsic FXase together with IXa, calcium 
and the phospholipid surface.  The intrinsic pathway generates a much larger amount 
of thrombin compared to the extrinsic pathway, due to its FXase being 50-100 fold 
more active (Lawson and Mann 1991; Ahmad, Rawala-Sheikh et al. 1992).  This is the 
final step of the intrinsic pathway and leads to the subsequent final common pathway. 
 
2.1.3 Final Common Pathway: 
When activated, FXa associates with its cofactor FVa in the presence of calcium and 
the phospholipid surface, to form a prothrombinase complex.  This complex 
subsequently converts prothrombin into thrombin.  By complexing with FVa, the rate 
of FXa mediated thrombin generation increases by 105 fold (Pryzdial and Mann 1991).  
Thrombin is the terminal serine protease of the coagulation cascade and its main action 
is to cleave fibrinogen to expose polymerisation sites.  These sites allow each fibrin 
molecule to form non-covalent bonds with two neighbouring fibrin molecules, forming 
double stranded protofibrils, which then arrange themselves into the three-dimensional 
network of the stable fibrin clot.  The structure of the polymerised fibrin is stabilised 
further by FXIIIa (which is activated by thrombin).  FXIIIa forms covalent bonds 
between fibrin molecules within each protofibril (Hornyak and Shafer 1992; Weisel, 
Francis et al. 1993). 
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2.1.4 Regulators of coagulation 
Tissue factor pathway inhibitor (TFPI) acts to inhibit the actions of the extrinsic FXase, 
in addition to FX (Broze, Warren et al. 1988; Rapaport 1991).  Thrombomodulin (TM) 
is expressed throughout the vascular endothelium (Esmon 1995) and binds with 
thrombin forming the IIa-TM complex, which in turn activates protein C (APC).  APC 
is an anti-coagulant that inhibits FV and FVIII activation.   
Antithrombin (AT), is present in low plasma concentrations and thus inactivates 
thrombin at a relatively slow rate.  In addition to thrombin, AT has an inhibitory effect 
on FIXa, FXa, FXIa and FXIIa and plasmin.   
 
Figure I: The Coagulation cascade (Escobar, Harmening et al. 2002) 
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2.2 Fibrinolysis 
 The fibrinolytic system removes thrombus that is formed during the repair of the 
vascular endothelium, restoring patency to the vessel.  However, the fibrinolytic system 
also has roles in tissue remodelling, tumour invasion, ovulation and in the implantation 
and early development of the fetus (Loskutoff 1988).  Plasmin is the central component 
of the fibrinolytic system and acts to lyse fibrin clots.  Plasmin is formed by the 
activation of its pro-enzyme plasminogen by fibrinolytic activators including tissue 
type plasminogen activator (tPA), which is released by the damaged vessel wall, and to 
a lesser extent, urokinase type plasminogen activator (uPA) which is present in low 
plasma concentrations.  Plasminogen activator inhibitors (PAI 1 produced by the 
endothelium and PAI 2 produced by the placenta) regulate the activity of tPA and uPA.  
PAI I acts upon cell surface receptors and matrix binding points, so its proteolytic 
actions are specifically localised.  This is important in the regulation of the fibrinolytic 
system (Rijken, Otter et al. 1990).  
Intravascular fibrinolysis is initiated when plasmin and tPA bind to lysines on the 
surface of fibrin (this is known as the initiation phase of fibrinolysis).  Plasmin partially 
degrades fibrin, exposing C-terminal lysine residues which have several positive 
feedback type actions: i) the C-terminal lysines upregulate plasmin generation by 
increasing plasminogen’s affinity for partially degraded fibrin and fibrin degradation 
products (FDP); ii) the conversion of Glu1-plasminogen to Lys78-plasminogen by 
plasmin, makes plasminogen a better substrate for tPA; and finally  iii) the C-terminal 
lysine residues decrease the rate of plasmin inhibition by α2-antiplasmin, which is 
unable to act upon plasmin bound to fibrin or FDP.  All of these actions greatly increase 
the efficacy of fibrinolysis, and these positive feedback loops are termed the 
acceleration phase of fibrinolysis.   
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Figure 2: The fibrinolytic pathway 
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2.3 Haemostasis in normal pregnancy 
Normal pregnancy is associated with changes in both the coagulation and fibrinolytic 
systems.  The concentrations of the majority of coagulation factors increase; levels of 
some physiological anticoagulants decrease and components of the fibrinolytic system 
are reduced (Bremme 2003; Brenner 2004). Overall, this creates a hypercoaguable state 
which is most marked towards term and persists through the post-partum period.  
Although these adaptations may be an important factor to limit blood loss during 
delivery and maintain placental function, they also increase the risk of venous 
thromboembolism during pregnancy and the puerperium.     
 
2.3.1 Changes in procoagulants: 
There is a progressive, significant rise in the levels of most coagulation factors 
including factor VII, VIII, X, XII, von Willebrand factor (VWF) and plasma fibrinogen 
(Stirling, Woolf et al. 1984; Aharon, Lanir et al. 2005; Kadir R 2009).  The increase in 
coagulation factor levels is generally most marked in the third trimester, possibly in 
preparation for delivery (Hellgren and Blomback 1981; Stirling, Woolf et al. 1984; 
Clark, Brennand et al. 1998; Kadir RA 1998; Kadir R 2009).  Factors II, V and IX have 
all been reported to be either slightly increased or unchanged during pregnancy (Nilsson 
and Kullander 1967; Stirling, Woolf et al. 1984).  
Plasma fibrinogen concentration in late pregnancy and labour is up to two fold non 
pregnant levels (Stirling, Woolf et al. 1984) and FVII can increase by up to ten fold.  
FVIII and VWF concentrations progressively increase from as early as six weeks 
gestation to peak at term and then return to pre pregnancy levels by six weeks post 
partum (Stirling, Woolf et al. 1984; Sanchez-Luceros, Meschengieser et al. 2003).  
Factor XI decreases slightly, reaching concentrations of 60-70% of the normal non 
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pregnant value and reaches a nadir at term (Hellgren and Blomback 1981).   Factor XIII 
(subunit A antigen) initially increases by 40% by mid pregnancy but then levels fall, 
reaching non pregnant levels by term (Persson, Stenberg et al. 1980).  Factors II and V 
remain unchanged during pregnancy (Stirling, Woolf et al. 1984). 
 
 
2.3.2 Changes in anticoagulants: 
Levels of TM, which when bound to thrombin activates Protein C, are decreased after 
32 weeks gestation (Boffa, Valsecchi et al. 1998). This is due to neutrophil activation 
which triggers proteolysis of endothelial TM, releasing soluble TM into the circulation.  
Despite TM levels being uniform amongst pregnancies until 12 weeks, the wide range 
reported after this gestation makes predicting preeclampsia or gestational hypertension 
using a TM reference curve unreliable (Boffa, Valsecchi et al. 1998).  However, a 
sudden increase from a baseline value in an individual can indicate an underlying 
placental vascular disorder.   
Protein C activity may fluctuate slightly during pregnancy but all values remain within 
the normal non-pregnant range (Gonzalez, Alberca et al. 1985; Aznar, Gilabert et al. 
1986; Gilabert, Fernandez et al. 1988; Bremme, Ostlund et al. 1992; Faught, Garner et 
al. 1995; Kjellberg, Andersson et al. 1999). Protein S exists either as functionally active 
free Protein S, or as an inactive complex bound to C4-B binding protein.  C4-B binding 
protein levels increase during pregnancy, but this accompanied by a fall in free protein 
S in the second and third trimesters (Gilabert, Fernandez et al. 1988; Brenner 2004). It 
remains unknown if the fall in free protein S contributes to the hypercoaguable state of 
pregnancy.  Overall, there is a progressive decrease of total protein S with increasing 
gestation (Comp, Thurnau et al. 1986; Lefkowitz, Clarke et al. 1996).  
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2.3.3 Fibrinolysis: 
At present, there is no consensus opinion on the changes in fibrinolytic activity during 
pregnancy.  Several studies report that fibrinolysis is increased during pregnancy (van 
Wersch and Ubachs 1991; Cadroy, Grandjean et al. 1993; Cerneca, Ricci et al. 1997; 
Uchikova and Ledjev 2005), whereas others report that it is suppressed, (Stirling, Woolf 
et al. 1984; Holmes, Wallace et al. 2002; Bremme 2003; Clark 2003) with normal levels 
being restored within 1 hour of delivery of the placenta (Stirling, Woolf et al. 1984).  
Furthermore, some authors are of the opinion that none of the observed changes in the 
components of the fibrinolytic system have an effect on overall fibrinolytic activity 
(Kruithof, Tran-Thang et al. 1987; Wright, Cooper et al. 1988).  
 
Previous reports of increased concentrations of fibrin degradation products (FDP) in 
pregnancy had led former authors to conclude that fibrinolysis activity was increased 
during pregnancy (Uchikova and Ledjev 2005). However, it has been suggested that 
increased levels of FDP such as D dimmers originate from the increased fibrin 
generation and degradation within the utero-placental unit (plasma D dimmer levels are 
higher in women who have a Caesarean section during labour compared to those who 
have an elective procedure), despite a reduced fibrinolytic potential in the systemic 
circulation (Bremme 2003). A further possible explanation for increased levels of 
circulating FDP is impaired clearance (Wright, Cooper et al. 1988).   
Increased levels of plasminogen inhibitors PAI 1 and 2 act to decrease levels of tissue 
plasminogen activator (tPA) (Bremme 2003; Brenner 2004). PAI 2 is produced by 
placental villous cells and is undetectable outside of pregnancy (Astedt, Hagerstrand et 
al. 1986).  There is a positive correlation between placental mass and PAI 2 levels (de 
	 23 
Boer, ten Cate et al. 1989). Furthermore, PAI 2 levels also vary with fetal size, 
suggesting that levels are dependant upon the quality as well as the quantity of placental 
tissue (He, Bremme et al. 1996).  
 
2.3.4 Thrombin generation: 
Activation of the coagulation cascade leads to the formation of thrombin.  Thrombin is 
a serine protease which has several actions including the formation of fibrin and the 
activation of platelets and factors V, VIII and XIII.  Thrombin generation starts to 
increase from as early as 7 weeks gestation to peak at term (Rosenkranz, Hiden et al. 
2008). Thrombin generation can be assessed by quantifying circulating levels of marker 
proteins formed during thrombin generation or inactivation.  These include soluble 
fibrin, thrombin-antithrombin complexes (TAT) and prothrombin fragments 1 and 2 
(F1 and 2).  In a study of 26 normal pregnant women, 50% had increased TAT levels 
in the first trimester and all of the participants had significantly increased levels during 
the second and third trimesters (Bremme, Ostlund et al. 1992). In addition, soluble 
fibrin was seen to increase progressively from the first trimester until term (Bremme, 
Ostlund et al. 1992). F1 and 2 have been demonstrated to be elevated beyond non-
pregnant levels from the first trimester and there is a positive correlation between 
gestation age and increased levels (Comeglio, Fedi et al. 1996). Elevated antenatal 
levels of soluble fibrin TAT and F1 and 2, suggest that increased thrombin generation 
is a feature of normal pregnancy (de Boer, ten Cate et al. 1989).  
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2.3.5 Placental Haemostasis: 
In addition to changes in systemic haemostasis, there is evidence of marked changes 
within the utero-placenta circulation. Maternal blood flows through the decidual 
arteries into the intervillous space and henceforth into the syncitiotophoblast cells.  In 
order to accommodate increasing maternal blood flow into the intervillous space, there 
is a physiological adaptation of the spiral arteries. Much of their vascular endothelium 
and underlying smooth muscle are replaced by trophoblasts.   For the placenta to 
function efficiently, there must be a balance of rapid activation and close local 
regulation of coagulation (Lanir, Aharon et al. 2003). As gestation increases, the 
syncitiotrophoblast starts to express coagulation components including VWF and the 
CD31 marker in addition to tissue factor (TF) (Kuczynski, Uszynski et al. 2002). TF, 
the primary cellular mediator of haemostasis, is also expressed on perivascular 
decidualized human endometrial stromal cells (HESC), in order to prevent 
haemorrhage as a result of trophoblastic invasion (Beller and Ebert 1982). In addition 
to their haemostatic actions, coagulation components including TF and TM have a role 
in placental blood vessel differentiation (Lockwood, Krikun et al. 2000).  
Placental fibrin deposits are seen in normal pregnancy (Clark and Greer 2003). This 
suggests that the decrease in fibrinolysis seen in plasma is a mechanism to inhibit fibrin 
degradation in the placenta to prevent haemorrhage during pregnancy and delivery.  
Furthermore, when compared with endothelial vasculature, trophoblasts exhibit a 
reduced capacity to lyse fibrin due to high levels of PAI 1 and 2 (Sheppard and Bonnar 
1999).  
Compared to maternal plasma, amniotic fluid contains higher levels of TF (Erez, 
Gotsch et al. 2009). Subsequently, amniotic fluid has procoagulant activity, with the 
ability to accelerate clot formation in in vitro testing (Weiner, Reid et al. 1949).   
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2.3.6 Platelets: 
Thrombocytopenia (a platelet count < 150) is the most common haemostatic 
abnormality found antenatally and affects 7.3-11.6% of normal term pregnancies 
(Bremme 2003). Antenatal thrombocytopenia does not warrant further investigation 
unless it is detected in early pregnancy, the patient is symptomatic or the platelet count 
is less than 100.  Platelet count progressively decreases with gestation, falling 
significantly between 12 and 24 weeks (Bremme, Ostlund et al. 1992).  There is an 
associated decrease in mean platelet volume (Fay, Hughes et al. 1983). This implies 
that there is increased platelet production to compensate for enhanced platelet 
destruction as a result of low-grade intravascular coagulation within the placenta (Fay, 
Hughes et al. 1983). Platelet activation and aggregation are also enhanced during 
pregnancy leading to increased plasma concentrations of CD63 (Holthe, Staff et al. 
2004) and b-thromboglobulin (Douglas, Shah et al. 1982).  
 
Pregnancy is associated with increased activation of the maternal coagulation cascade 
resulting in increased thrombin generation.  This may be a consequence of a 
combination of factors including altered hormone-influenced synthesis, an increased 
volume of distribution and increased catabolism.  This hypercoagulable state is a 
physiological response to the haemostatic challenges of pregnancy.  However, 
abnormalities of the thrombotic/ antithrombotic balance in early pregnancy may act as 
markers for subsequent vascular disorders including pre-eclampsia. 
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2.4 Thrombin activatable fibrinolysis inhibitor Protein: 
2.4.1 Discovery: 
In 1989, two independent studies identified the proteins with carboxypeptidase activity 
distinct from the constitutively active plasma carboxypeptidase N (Campbell and 
Okada 1989; Hendriks, Scharpe et al. 1989).  The proteins were named unstable 
carboxypeptidase (CPU) and arginine carboxypeptidase (CPR).  In 1991, Eaton et al 
isolated a plasminogen binding protein (plasma pro CPB) with an amino acid sequence 
similar to pancreatic carboxypeptidase B (Eaton, Malloy et al. 1991), and in 1995 
Bajzar et al characterized a carboxypeptidase which, once activated by thrombin, 
attenuated clot lysis (Bajzar, Manuel et al. 1995).  The presence of these proteins in 
plasma can explain the anti-fibrinolytic effect of the activation of prothrombin during 
t-PA activated fibrinolysis.  Eventually, amino acid terminal sequencing revealed that 
all four of the proteins identified (CPU, CPR, plasma pro CPB and TAFI) were identical 
(Vanhoof, Wauters et al. 1996). 
 
2.4.2 Synthesis of TAFI: 
TAFI is encoded by the CPB2 gene that is located on chromosome 13 (13q14.11) 
(Eaton, Malloy et al. 1991).  Nineteen single nucleotide polymorphisms (SNP) have 
been detected in the CPB2 gene (Boffa, Maret et al. 2008) of which six are located 
within the coding region.  Two of these SNPs produce an amino acid substitution:  
+505G/A and +1040C/T which give rise to an Ala/Thr substitution at position 147 and 
Thr/Ile substitution at position 325 respectively (Zhao, Morser et al. 1998; Brouwers, 
Vols et al. 2001).  Only one of these polymorphisms, located at position 325, results in 
an amino acid substitution which affects TAFI’s function by increasing TAFI’s half-
life two fold (Schneider, Boffa et al. 2002). 
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TAFI is predominantly synthesised in the liver and is present in plasma as a zymogen 
(Bouma, Marx et al. 2001).  TAFI is also produced in megakaryocytes, but this only 
accounts for 0.1% of the total circulating TAFI concentration (Declerck 2011).  Despite 
the relatively small amount released by platelets, the local boost of TAFI at the site of 
thrombus formation has a significant impact on fibrinolysis as only small quantities of 
TAFI are required to affect clot lysis.  The local secretion of TAFI may also account 
for platelet-mediated resistance to fibrinolysis.  Circulating TAFI levels range between 
73-275 nm (4-15 µg ml-1) (Foley JH 2013).  This wide variation has been attributed to: 
different isoforms of TAFI having differing reactivity to commercially available 
ELISA assays and altered TAFI gene expression as a result of hormonal control, the 
action of various disease states and SNPs changing mRNA stability (Gils, Alessi et al. 
2003; Boffa MB 2007; Boffa, Maret et al. 2008).   
 
2.4.3 TAFI activation 
TAFI is formed of a catalytic domain joined to a N-terminal activation peptide via a 
linker region (Marx, Brondijk et al. 2008).  The zymogen TAFI is converted into its 
active form (TAFIa) by the proteolytic cleavage of the Arg92-Ala93 bond by either 
thrombin or plasmin.  Thrombin is a weak activator of TAFI.  However, when 
complexed with thrombomodulin (a transmembrane protein expressed on the surface 
of endothelial cells) its efficacy of TAFI activation is increased 1250 fold (Bajzar, 
Morser et al. 1996) .  Binding to thrombomodulin modulates the substrate specificity 
of thrombin so that it is no longer recognised by fibrinogen and other substrates.  Instead 
the thrombin-thrombomodulin complex (T/TM) produces activated protein C (APC) an 
anticoagulant which acts against the 1250 fold increase in TAFI activation to prevent 
massive coagulation (Declerck 2011).  Thus clot formation is localised to the site of 
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vascular injury.  TAFI can also be activated by plasmin, a stronger activator than 
thrombin (Mao, Cooper et al. 1999).  TAFI ‘s activation by plasmin results in TAFI 
generation adjacent to fibrin thus preventing premature clot lysis.   
 
2.4.4 Physiological roles of TAFI 
2.4.4.1 The attenuation of fibrinolysis: 
Fibrinolysis is essential for haemostasis and enables the removal of the haemostatic 
plug upon repair of vascular damage.  Furthermore, in conjunction with physiological 
anticoagulants, it limits pathological propagation of the fibrin clot, thus maintaining 
vessel patency. Tissue plasminogen activator (t-PA) converts plasminogen to plasmin.  
This reaction initiates fibrinolysis.  The plasmin then acts on the fibrin clot which is 
partially degraded, leaving exposed C-terminal lysine residues on its surface.  These C-
terminal lysine residues act to produce a burst of plasmin generation and thus play an 
important role in the regulation of fibrinolysis.  The lysine residues have 4 main actions: 
i) they bind plasminogen and this accumulation leads to a burst of plasmin generation 
at the clot surface; ii) the lysine residues induce conformational changes in the structure 
of plasminogen, making it a better substrate for conversion to plasmin by t-PA (Fleury 
and Angles-Cano 1991); iii) Plasmin also binds to the lysine residues which protects it 
from inactivation by α2- antiplasmin and iv) partially degraded fibrin acts as a co-factor 
in plasmin mediated conversion of Glu-plasminogen to Lys-plasminogen, a better 
substrate for t-PA (Hoylaerts, Rijken et al. 1982).  TAFI removes the C-termial lysines 
from partially degraded fibrin, thus inhibiting fibrin’s co-factor role in plasminogen 
activation.  This dramatically decreases the fibrinolytic activity of t-PA.   
TAFI function is dependent on its concentration reaching a threshold value determined 
by plasmin concentration: higher TAFI concentrations are required to inhibit 
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fibrinolysis with higher plasmin concentrations.  Plasmin concentration is determined 
by local levels of plasminogen activation that are, in turn, regulated by local 
concentrations of plasminogen activators and inhibitors.  Factors that direct TAFIa 
concentration include: plasma TAFI levels, the extent of their activation and TAFIa’s 
intrinsic stability.  The most significant of these factors is the rate of TAFI activation.  
Large rapid increases in TAFIa levels inhibit fibrinolysis far less efficiently than a small 
sustained release of TAFIa (Colucci and Semeraro 2012)  
TAFIa affects fibrinolysis even when as little as 1% of local TAFI zymogen has been 
activated.  It has been demonstrated that the TAFI zymogen has some enzymatic 
activity, although with much less catalytic efficiency than TAFIa (Valnikova Z 2007).  
However, TAFI zymogen has double the substrate affinity than TAFIa, which, in part, 
may compensate for its reduced catalytic efficency (Valnikova Z 2007).  The zymogen 
can cleave small substrates but has a limited capability to act on plasmin modified fibrin 
degradation products (Foley JH 2008).  
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Figure 3: Role of TAFI in fibrinolysis 
 
 
 
2.4.4.2 Role of TAFI in inflammation: 
Other substrates for TAFIa have been identified including: bradykinin, thrombin 
cleaved osteopontin and activated complement factors C3a and C5a (Shinohara, 
Sakurada et al. 1994; Campbell, Lazoura et al. 2002).  This suggests that TAFI’s actions 
are not limited to inhibiting fibrinolysis, but may have a broader role as an anti-
inflammatory, affecting cell migration and wound healing.  Thrombin can act as either 
as a pro-coagulant or an anti-inflammatory at sites of inflammation.  It achieves the 
anti-inflammatory actions by binding to thrombomodulin (TM) to activate APC and 
TAFIa.  TAFIa then cleaves kinins, analphylatoxins and thrombin cleaved ostepontin, 
rendering them inactive (Myles, Nishimura et al. 2003).   
TAFI’s role as an anti-inflammatory agent was previously overlooked due to 
Carboxypeptidase N (CPN) masking TAFI’s action on inflammatory mediators 
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(Skidgel RA 2007).  Unlike TAFI, CPN does not require activation (Skidgel RA 2007; 
Walker JB 2008).   
C5a is a potent inflammatory mediator and acts by: recruiting and activating neutrophils 
(Mollnes TE 2002), increasing vascular permeability (Mulligan MS 1996; Liu ZM 
2010)  and stimulating smooth muscle contraction (Scheid CR 1983).  Additionally, 
C5a can release tissue necrosis factor (TNF) and histamine from the lysosomal 
degredation of inflammatory cells (el-Lati SG 1994; Kikuchi Y 2002).  A study of C5a 
activated alveolitis in mice demonstrated significantly decreased inflammation in TAFI 
deficient mice compared with wild mice (Nishimura T 2007).  The same study 
examined the effects of infusion of mutated thrombin capable of TAFI activation but 
not clot generation.  Wild type mice were further protected against inflammation in 
direct contrast to TAFI deficient mice (Nishimura T 2007).  Through its inactivation of 
C5a, TAFIa may protect against inflammation.   
 
2.4.5 Instability of TAFIa 
TAFIa is rendered inactive by conformational changes that result in the exposure of a 
cleavage site at Arg302 allowing subsequent proteolytic cleavage by T/TM or plasmin 
(Marx, Brondijk et al. 2008).   TAFIa demonstrates a variable half-life dependent upon 
temperature.  It varies from eight minutes at 37°C to several hours at 22°C (Brouwers, 
Vols et al. 2001; Schneider, Boffa et al. 2002).  TAFIa instability is also affected by the 
presence of the polymorphism at position 325.  When the polymorphism results in an 
I325 variant, TAFIa’s half-life is doubled (Schneider, Boffa et al. 2002).  The I325 variant 
has been associated with reduced inflammation in addition to a longer anti-fibtinolytic 
effect (Schneider, Boffa et al. 2002; Gregersen, Leung et al. 2011).  No physiological 
inactivators for TAFIa have been reported, thus its intrinsic instability contributes to its 
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regulation, which is supported by the fact that more stable variants have a higher anti-
fibrinolytic activity (Ceresa, Peeters et al. 2007).   
 
2.4.6 TAFI inhibitors 
TAFIa is inactivated by chelating agents, e.g. EDTA (Willemse, Heylen et al. 2009).  
Several low molecular weight non specific inhibitors have been identified including 
reducing agents and small synthetic substrate analogues (Willemse, Heylen et al. 2009).  
The disadvantage of these inhibitors is that they also inhibit other carboxypeptidases 
including CPN and pancreatic carboxypeptidase CPB (Willemse, Heylen et al. 2009).  
More potent selective TAFIa inhibitors are in development (Willemse, Heylen et al. 
2009).  Potato tuber carboxypeptidase (PTCI) is naturally occurring and competitively 
inhibits TAFIa (Schneider and Nesheim 2003).  PTCI has a biphasic affect: it attenuates 
clot lysis at low concentrations and enhances lysis at high concentration.  The initial 
attenuation can be explained by the conformational changes in TAFI caused by binding 
to PTCI.  Gradually, large amounts of TAFIa-PTCI complexes accumulate. Thus, when 
the complexes gradually disassociate rendering TAFI active once more, there is a large 
local burst of TAFIa.  As PCTI does not inhibit CPN it is widely used in clot lysis 
assays (Schneider and Nesheim 2003).   
Attenuating TAFI synthesis and/or activation can also inhibit TAFIa.  Several 
monoclonal antibodies that inhibit TAFI activation have been produced (Gils, Ceresa 
et al. 2005; Hillmayer K 2008; Buelens K 2010).  These monoclonal antibodies either 
act directly to inhibit TAFIa activity or its activation (Foley JH 2008). Selective TAFIa 
inhibitors would have several clinical applications.  Their use as an adjunct to 
thrombolytic agents could decrease the dosage needed to be therapeutic.  This in turn 
may decrease bleeding complications associated with thrombolytic therapy.  Animal 
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studies demonstrated significantly lower perfusion times and thrombus weights when 
PTCI was administered in conjunction with thrombolytic therapy (Klement P 1999) 
and enhanced thrombolysis when low concentrations of tPA were used with a selective 
TAFIa inhibitor (Wang YX 2007).   
There is conflicting data about the use of TAFI inhibitors as sole agents in the treatment 
of thrombotic conditions (Foley JH 2008).  The administration of PTCI after the 
formation of arterial or venous thrombosis did not increase fibrinolysis in two animal 
studies (Klement P 1999; Nagashima M 2000), whereas other studies demonstrated that 
PTCI and synthetic TAFI inhibitors decreased arterial and venous fibrin deposition and 
increased lysis of microthrombi (Hashimoto M 2002; Muto Y 2003).  In addition, 
monoclonal antibodies that inhibit TAFIa increased fibrinolysis in e. coli induced sepsis 
in animal studies (Binette TM 2007).  Despite the conflicting data, it is possible to 
conclude that TAFIa modulates fibrinolysis and the effect produced by TAFI inhibitors 
is dependant of the timing of administration and the cause of thrombosis.   
 
 
2.4.7 Pathophysiology of TAFI 
Thrombotic disorders may be due to impaired fibrinolysis resulting from increased 
levels of TAFI, in addition to increased thrombin formation.  This is supported by 
reports of elevated TAFI levels seen in patients with venous thrombosis (Schroeder, 
Kucher et al. 2003) and men awaiting coronary bypass grafting to treat stable angina 
pectoris (Silveira, Schatteman et al. 2000).  In addition, epidemiological studies have 
demonstrated elevated TAFI levels in stroke patients (Montaner, Ribo et al. 2003; 
Santamaria, Oliver et al. 2003).  However, there is also data in the literature that do not 
support the theory that thrombotic events are attributable to high TAFI levels.  Several 
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studies show no difference in TAFI concentration in patients who suffer a myocardial 
infarction and controls (Juhan-Vague, Morange et al. 2002; Schroeder, Chatterjee et al. 
2002; Juhan-Vague and Morange 2003; Salomon, Steinberg et al. 2003).  In one large 
international multicentre study which compared 498 patients who suffered a 
myocardial infarction to 553 age matched controls, no significant difference in TAFI 
levels were seen (Juhan-Vague, Morange et al. 2002).  Furthermore, fewer patients than 
controls had a TAFI level greater than the 90th centile (Juhan-Vague, Morange et al. 
2002).  The different conclusions drawn by these studies may be in part due to the use 
of different methods to determine TAFI activity/ antigen levels.  Isoforms of TAFI 
demonstrate different reactivity to some of the commercially available ELISAs.  Thus, 
TAFI-I325 (which has greater fibrinolytic effect due to its longer half life) can be 
underestimated leading to an incorrect overall TAFI activity.  Therefore, only well 
characterised assays which assess TAFI activity rather than antigen levels should be 
used in further studies.   
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Table 1: Studies of changes in TAFI Ag and TAFIa in Normal pregnancy and 
PET 
 
 
 
REFERENCE 
 
STUDY 
DESIGN 
 
NUMBER OF 
PARTICIPANTS 
 
ASSAYS 
PERFORMED 
 
RESULTS 
(Chetaille, 
Alessi et al. 
2000) 
Case 
control 
12 Normal 
pregnancies 3rd 
Trimester 
 
Age matched non 
pregnant controls 
(n not specified) 
TAFI Ag ELISA 
(Milan Analytica) 
Patient group: 95+/- 35 (%) 
 
Control Group: 95+/-39 (%) 
(Chabloz, 
Reber et al. 
2001) 
Cross 
sectional 
144 Normal 
pregnancies 
TAFI Ag ELISA 
(Milan Analytica) 
Data expressed as box plots only, no numerical data. 
Significant increase in TAFI Ag levels between 10-14 weeks and 
25-40 weeks 
No significant increase in TAFI Ag after 29 weeks  
(Antovic, 
Rafik Hamad 
et al. 2002) 
Case 
control 
38 PET 
16 Normal 
pregnant controls 
TAFI Ag ELISA 
(Affinity 
Biologicals) 
Patient group: 48.89 mcg/ml (mean) 
Control Group: 116.3 mcg/ml (mean) 
(Alacacioglu, 
Ozcan et al. 
2004) 
Case 
control 
30 PET 
30 Normal 
pregnant controls 
TAFI Ag ELISA 
VisuLise™ 
Patient group: 12.55 +/- 1.88 (mcg/ml) 
Control group: 12.29+/-3 (mcg/ml) 
(Mousa, 
Downey et al. 
2004) 
Cross 
sectional 
152 normal 
pregnancies 
TAFI Ag ELISA 
(Affinity 
Biologicals) 
 
10-14 weeks: 6.6+/- 1.2 (mcg/ml) 
25-29 weeks: 8.2 +/-2.3 (mcg/ml) 
35-39 weeks: 9.6 +/- 2 (mcg/ml) 
within 24 hours of delivery: 7.2 +/- 1.1 (mcg/ml) 
(Acosta-
Tejeda, 
Baptista-
Gonzalez et 
al. 2011) 
Case 
control 
87 PET 
87 Normal 
pregnant controls 
TAFI Ag ELISA 
(Actichrome) 
Patient group: Median (range) 20.4 mcg/ml (17.3-23.5)  
Control group: Median (range) 13.3 mcg/ml(12.06-14.55) 
(Watanabe, 
Wada et al. 
2001) 
Cross 
sectional 
176 Normal 
pregnancies 
TAFIa 
TAFFI Acivity Kit 
(American 
diagnostica) 
6-11 weeks: 2.57 +/- 1.05mcg/ml 
18-22 weeks: 3 +/- 0.99 mcg/ml 
28-32 weeks: 3.07 +/- 0.99mcg/ml 
37-39 weeks: 3.21 +/- 0.92mcg/ml 
12-36 hours post delivery: 2.69 +/- 1.17mcg/ml 
(Zhang, Hu et 
al. 2008) 
Case 
control 
10 PET 
30 Normal 
pregnant controls 
TAFI Ag ELISA 
(American 
Diagnostica) 
Patient group: 
1st trimester 106.64+/- 19 (%) 
2nd trimester 129.23 +/-25.05 (%) 
3rd trimester 139.14 +/- 30.12 (%) 
 
Control group: 
1st trimester 85.35+/- 24.69 (%) 
2nd trimester 99.65 +/- 18.27 (%) 
3rd trimester 110.12+/- 23.36 (%) 
 
 
 
 
 
	 36 
2.4.8 TAFI in pregnancy 
2.4.8.1 TAFI in normal pregnancy: 
There are contrasting reports of TAFI levels during pregnancy (Chetaille, Alessi et al. 
2000; Chabloz, Reber et al. 2001; Watanabe, Wada et al. 2001; Mousa, Downey et al. 
2004).  Three out of the four published studies considering TAFI Ag and TAFIa in 
normal pregnancy, demonstrate a significant progressive increase from early pregnancy 
(Chabloz, Reber et al. 2001; Watanabe, Wada et al. 2001; Mousa, Downey et al. 2004).  
Chabloz et al performed a cross sectional cohort study assessing TAFI Ag and D-dimer 
levels in 144 women with uncomplicated singleton pregnancies (Chabloz, Reber et al. 
2001).  They reported a steady significant increase in TAFI Ag levels between 10 and 
25 weeks gestation, after which, TAFI Ag levels plateaued until they started to fall after 
delivery (Chabloz, Reber et al. 2001).  As Chabloz et al did not include any non-
pregnant controls, the study could not confirm if TAFI Ag levels were increased when 
compared to outside of pregnancy. 
 
A more recent cross sectional case control study by Watanabe et al focused on changes 
in TAFIa during pregnancy (Watanabe, Wada et al. 2001).  This prospective study 
demonstrated significantly higher TAFIa in 176 women with normal pregnancies 
compared to 15 non-pregnant women and confirmed a progressive increase in TAFIa 
starting in the first trimester, continuing up to 20 weeks after which levels remained 
steady until they started to decrease postnatally (Watanabe, Wada et al. 2001).  This is 
one of the few studies which examines TAFI activity in normal pregnancy (Watanabe, 
Wada et al. 2001).   
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Another cross sectional study of 183 normal pregnancies measured TAFI Ag levels at 
four weekly intervals and reported a progressive increase in TAFI Ag throughout 
pregnancy, maximal at 35-39 weeks gestation, and a gradual decline in the levels post 
delivery (Mousa, Downey et al. 2004).  Although it did not report changes in TAFIa, 
this study did examine TAFI’s functional effect by measuring CLT, both with and 
without the addition of a TAFI inhibitor.   The changes in CLT mirrored those of TAFI 
Ag, increasing with gestation.  Thus, there is a progressive impairment of fibrinolysis 
as pregnancy progresses.  Addition of the TAFI inhibitor during the CLT assay 
abrogated the increase in CLT, suggesting that the decreased rate of fibrinolysis is 
attributable to TAFI (Mousa, Downey et al. 2004).   
 
In contrast to the three studies previously described, Chetaille et al reported that 
pregnancy had no influence on TAFI Ag levels (Chetaille, Alessi et al. 2000). This large 
cross sectional study examined TAFI Ag levels in 249 healthy subjects (139 males, 110 
non pregnant females and 12 pregnant women in their third trimester) (Chetaille, Alessi 
et al. 2000).  Neither gender, nor pregnancy had any influence on mean TAFI Ag levels 
(Chetaille, Alessi et al. 2000).  The discrepancy between this and other studies is most 
likely attributable to the small sample size and the large inter-individual variation in 
TAFI Ag levels (Chetaille, Alessi et al. 2000).   
 
2.4.8.2 TAFI in Pre-eclampsia: 
A handful of studies have investigated TAFI levels in PET and have produced 
conflicting reports (Antovic, Rafik Hamad et al. 2002; Alacacioglu, Ozcan et al. 2004; 
Dusse, Cooper et al. 2007; Zhang, Hu et al. 2008; Martinez-Zamora, Tassies et al. 2010; 
Acosta-Tejeda, Baptista-Gonzalez et al. 2011). Antovic et al performed a case control 
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study to evaluate the role of impaired fibrinolysis in PET and IUGR (Antovic, Rafik 
Hamad et al. 2002).  The study measured third trimester levels of TAFI Ag, in 46 
women with PET (eight of whom also had IUGR) and 16 normal pregnant controls.  
The study reported significantly lower mean TAFI Ag levels in the patient group (49 
compared to 116 in the control group) (Antovic, Rafik Hamad et al. 2002).  The study 
also measured CLT and overall fibrinolytic potential in 15 women in the patient group 
and 10 controls.  In 10 (67%) women from the patient group, clot lysis was not achieved 
after two hours, compared to no women in the control group.  Furthermore, in the 
remaining five (33%) women with PET, CLT was significantly longer than in the 
control group.  However, the difference in mean CLT was not statistically different 
between the two groups.  Overall fibrinolytic potential was significantly lower in the 
patient group.  However, addition of PTCI (a TAFI inhibitor) did not increase the 
overall fibrinolytic potential in the patient group.  Thus, it can be concluded that 
although fibrinolysis was impaired in women with PET and/ or IUGR, TAFI Ag levels 
did not contribute to the situation (Antovic, Rafik Hamad et al. 2002).  The low TAFI 
levels in PET were attributed to impaired liver function and increased urinary excretion 
(Antovic, Rafik Hamad et al. 2002).   However, to confirm the role of renal and hepatic 
impairment, urinary TAFI Ag levels would have to be measured.  This study is also 
limited by its small sample size and by the fact that only TAFI Ag levels and not activity 
were measured.  Furthermore, the study only included women in their third trimester.  
Alacacioglu et al performed a similar case control study involving 30 women with PET 
and 30 pregnant controls in their third trimester, and found that despite a trend for 
marginally higher TAFI Ag levels in pre-eclamptic women, there was no significant 
difference in TAFI Ag levels between the two groups (Alacacioglu, Ozcan et al. 2004).  
The authors speculated that the underlying reason for the difference in their findings 
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from Antovic et al was the severity of PET in their patient group.  Only 7% of their 
patient group suffered from severe PET, compared to 63% in Antovic et al (Antovic, 
Rafik Hamad et al. 2002).  Thus, their degree of hepatic and renal impairment was 
lower than in the previous study.  Again, the findings of this study may not have 
achieved statistical significance due to its small sample size.   Moreover, only TAFI Ag 
was reported, again, solely in the third trimester (Alacacioglu, Ozcan et al. 2004).   
More recent studies have demonstrated higher TAFI Ag levels in pre-eclamptic women 
than in normal controls (Zhang, Hu et al. 2008; Martinez-Zamora, Tassies et al. 2010; 
Acosta-Tejeda, Baptista-Gonzalez et al. 2011).  Zhang et al reported results from 10 
women with PET, 12 with GHT and 30 normal controls.  Samples were collected in 
each trimester.  The study demonstrated significantly higher TAFI Ag levels in women 
with PET when compared to women with gestational hypertension (GHT) and normal 
pregnant controls at all gestations (Zhang, Hu et al. 2008).  However, there was no 
significant difference in TAFI Ag levels between women with GHT and the control 
group.  Importantly, this study demonstrated that significantly higher mean TAFI Ag 
levels were evident in the PET group from the first trimester, prior to the manifestation 
of clinical symptoms (Zhang, Hu et al. 2008).   Thus TAFI could be used as a marker 
to identify women at risk of PET enabling improved antenatal surveillance and prompt 
treatment.   
Martinez-Zamora et al investigated the changes in CLT and TAFI Ag levels in 76 
normal pregnant controls and 82 women with PET (Martinez-Zamora, Tassies et al. 
2010).  The study also examined TAFI Ag levels and CLT at six weeks postpartum.  
Amongst the control group there was a progressive increase in TAFI Ag levels from 
the first to the third trimester, which then dropped after delivery.  There was no 
statistically significant difference in TAFI Ag levels or CLT between the patient and 
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control groups during pregnancy.    However, women with PET had significantly higher 
postpartum TAFI Ag levels and longer CLT than the controls, thus demonstrating 
impaired fibrinolysis after delivery (Martinez-Zamora, Tassies et al. 2010).   
The most recent study to date evaluated the role of TAFIa in PET (Acosta-Tejeda, 
Baptista-Gonzalez et al. 2011).  In this case control study, TAFIa levels amongst 174 
women (87 women with PET and 87 normal controls) were measured after 20 weeks 
gestation.  Mean TAFIa levels were significantly higher in the PET group compared to 
the controls (20.4 µg/ml vs 13.3 µg/ml p=0.003).  In addition, the study also examined 
if TAFI SNP (G505A, C1040T and G-438A) were associated with PET.  The allele 
frequency and genotype of the polymorphisms were not associated with an increased 
risk of PET (Acosta-Tejeda, Baptista-Gonzalez et al. 2011).  This suggests that the 
increased levels of TAFIa described were attributable to PET rather than the presence 
of different polymorphisms.   
 
Increasingly, data available in the literature supports the view that TAFI is further 
increased from normal pregnancy levels in conditions including PET and IUGR 
(Antovic, Rafik Hamad et al. 2002; Acosta-Tejeda, Baptista-Gonzalez et al. 2011).  If 
this is confirmed, it may be the case that anti-TAFI agents may have a role in the 
treatment of these conditions.      
  
 
 
2.4.8.3 TAFI in Recurrent miscarriage and implantation failure 
Miscarriage is the most common complication of pregnancy and affects 15% of women, 
most frequently during the first trimester (Clark, Coulam et al. 2001).  The majority of 
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these losses are sporadic and do not recur.  However, 2-5% of women experience 
recurrent miscarriages (RM)(Clark, Coulam et al. 2001).  Repetitive pregnancy loss 
suggests an underlying cause and there has been a great deal of interest in defining a 
mechanism of RM.  Unfortunately, a cause is only isolated in 50% of RM patients (430 
2009)Li TC et al Hum Reprod Update 2002;8:463-81).   
 
It has been proposed that recurrent implantation failure (RIF) following embryo transfer 
(ET) in IVF is part of the spectrum of RM and that the two represent different 
manifestations of the same disease process (Martinez-Zamora, Creus et al. 2011).    
Indeed, both RIF and RM can be a result of embryonic chromosomal abnormalities or 
the same abnormalities in maternal endocrine, immunological or haemostasis 
(Christiansen, Nielsen et al. 2006; Stern and Chamley 2006).   Five percent of women 
in their first miscarriage and 30-40% of women undergoing IVF who subsequently 
miscarry will have a karyotypically normal pregnancy (Clark, Coulam et al. 2001).  
This increases the chance of RM or recurrent implantation failure (RIF) (Boue et al 
Teratology 1973;12:11-26) and suggests an underlying cause other than embryonic 
chromosomal abnormality.  It has been proposed that alterations in maternal 
haemostasis result in thrombosis of the uteroplacental vessels causing recurrent 
reproductive failure (Rai 2003).  
 
 
Several studies have investigated the role of TAFI in RM and RIF (Folkeringa, 
Korteweg et al. 2009; Knol, Veeger et al. 2009; Masini, Ticconi et al. 2009; Martinez-
Zamora, Creus et al. 2010; Martinez-Zamora, Tassies et al. 2010; Pruner, Djordjevic et 
al. 2010; Martinez-Zamora, Creus et al. 2011; Colucci and Semeraro 2012; Legnani, 
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Bovara et al. 2012) producing conflicting reports.  Several studies report lower levels 
of TAFI in women with RM when compared to controls (Folkeringa, Korteweg et al. 
2009; Masini, Ticconi et al. 2009; Legnani, Bovara et al. 2012) and go on to suggest 
that higher TAFI levels confer a protective effect against RM (Knol, Veeger et al. 
2009). 
 
Legnani et al performed a case control study including 140 women with a history of 
RM and 140 controls (Legnani, Bovara et al. 2012).  They reported significantly lower 
TAFIa levels in women with either three or more consecutive losses or two 
miscarriages with normal karyotyping in at least one pregnancy.   Women in the control 
group had no history of miscarriage.  The authors proposed that enhanced fibrinolysis 
was detrimental to implantation.  This theory was supported by evidence of higher rates 
of RM in women with Factor XIII deficiency, afibrinogenaemia and 
dysfibrinogenaemia, all conditions which demonstrate inadequate or defective fibrin 
(Inbal and Muszbek 2003) .  In addition, hypofibrinolysis is associated with lower 
levels of fibrin degredation products which induce apoptosis in placental trophoblast 
cells (Guo, Hernandez et al. 2009).    TAFIa has been shown to inactivate bradykinin, 
C3a and C5a in vivo (Myles, Nishimura et al. 2003).  The authors also suggested that 
TAFIa’s role in reducing inflammation may play a role in the pathophysiology of RM 
(Legnani, Bovara et al. 2012). 
 
There are several limitations to this study.  In addition to the limited sample size and 
retrospective design, the control group included women who had never been pregnant.  
Thus, it is unknown if they had they would be able to become pregnant, or go on to 
have a live birth.   
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Folkeringa et al performed a retrospective study examining TAFIa levels in 843 women 
(Folkeringa, Korteweg et al. 2009).  They divided the cohort into two groups: those 
with elevated TAFIa and those with normal levels and found no significant difference 
in rates of miscarriage between the two groups, (22.5% vs 27.9% respectively p=0.128) 
(Folkeringa, Korteweg et al. 2009).  Further sub-analysis revealed significantly reduced 
rates of recurrent miscarriage in women with high TAFIa (3.8% vs 7.9% p=0.041) 
(Folkeringa, Korteweg et al. 2009).  This study is limited in several ways.   Firstly, its 
retrospective design introduces the possibility of recall bias regarding fetal loss.  
Furthermore, the study group contains women who have experienced only one 
miscarriage making it more likely that aneuploidy was the cause of pregnancy loss; 
women with known thrombotic disorders were not excluded and none of the 
participants were investigated for other causes of miscarriage.  The authors do not 
clarify their definition of RM (two or more consecutive losses or three or more).   
 
A case control study by Masini et al reviewed 86 women who suffered two or more 
miscarriages and 72 women who had at least two children and no personal experience 
of miscarriage (Masini, Ticconi et al. 2009).  They reported a significantly higher 
frequency of the genotypes +505A/A and +1583A/A in the control group (Masini, 
Ticconi et al. 2009).  These genotypes have been seen to result in higher TAFI Ag levels 
(Frere, Morange et al. 2005).  The +505G/G genotype which correlates with lower 
TAFI Ag levels (Frere, Morange et al. 2005) and was more commonly seen in women 
with RM (Masini, Ticconi et al. 2009).   Although the authors defined RM as two or 
more losses, a sub analysis revealed the same findings when the RM group were 
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stratified according to the number of miscarriages that they had experienced (two or 
three or more) (Masini, Ticconi et al. 2009).   
 
Masini et al’s findings were supported by a further genetic case-control study which 
revealed significantly higher frequency of the +1040T/T genotype in women with RM 
(Pruner, Djordjevic et al. 2010).   However, neither of these genetic studies were 
accompanied by the parallel quantification of TAFIa or TAGFI Ag levels (Masini, 
Ticconi et al. 2009; Pruner, Djordjevic et al. 2010). 
 
In contrast to the aforementioned genetic studies (Masini, Ticconi et al. 2009; Pruner, 
Djordjevic et al. 2010), Martinez –Zamora et al found no significant difference in the 
distribution of TAFI polymorphisms case control studies of women with unexplained 
RM (Martinez-Zamora, Creus et al. 2010) or women with recurrent implantation failure 
(RIF) after IVF (Martinez-Zamora, Creus et al. 2011).   
 
The variation in TAFI Ag levels in the normal population can in part be attributed to 
genetic factors, but the relationship between TAFI SNPs, antigen levels and the risk of 
thrombotic complications remains poorly understood (Gris, Schved et al. 1990; Rai, 
Tuddenham et al. 2003).  
 
Two studies revealed significantly higher levels of TAFI Ag and longer CLT in women 
with reproductive failure when compared to controls (Martinez-Zamora, Creus et al. 
2010; Martinez-Zamora, Creus et al. 2011).  The first investigated 119 women with RM 
and 64 controls (Martinez-Zamora, Creus et al. 2010) and the second 30 women with 
RIF after IVF and 60 controls (Martinez-Zamora, Creus et al. 2011).  The women in 
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the control groups of both studies   had had a live birth after an uncomplicated 
pregnancy and no history of miscarriage.  All the RM patients had suffered three or 
more losses and all other causes of RM (including thrombotic disorders) were excluded 
(Martinez-Zamora, Creus et al. 2010).  
 
Women with RM are in a prothrombotic state even outside of pregnancy (Regan and 
Rai 2002; Rai 2003; Sebire, Backos et al. 2003).  As yet, it is not understood how  
thrombophilic factors impact on RM and RIF. 
 
 
Ovulation, implantation and placentation are all reliant on haemostatic mechanisms, 
with the fibrinolytic system regulating early trophoblastic invasion.  (Briefly), plasmin 
both activates matrix metallproteinases and degrades certain parts of the extracellular 
matrix of the decidua to allow trophoblastic invasion (Lala and Chakraborty 2003).  It 
follows that altered fibrinolysis results in decreased trophoblastic invasion.    
 
This provides a biological basis for disordered fibrinolysis’ role in reproductive failure.  
Previous studies suggest that hypofibrinolysis may be involved in early pregnancy loss 
(Gris, Schved et al. 1990; Coulam, Jeyendran et al. 2006; Sotiriadis, Makrigiannakis et 
al. 2007).  The two studies by Martinez Zamora et al (Martinez-Zamora, Creus et al. 
2010; Martinez-Zamora, Creus et al. 2011) demonstrated a significant direct 
relationship between CLT and TAFIag levels across all their study populations which 
lead to the conclusion that the impaired fibrinolysis seen in women with reproductive 
failure can be attributed to increased TAFIag levels.     
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Both studies demonstrating increased levels of TAFIag in women with reproductive 
failure had stringent inclusion criteria (Martinez-Zamora, Creus et al. 2010; Martinez-
Zamora, Creus et al. 2011).  All women in the affected groups had suffered at least 
three miscarriages/ implantation failures who had had all other causes of RM/ RIF 
excluded. In addition, these studies included CLT to reflect global haemostasis 
(Martinez-Zamora, Creus et al. 2010; Martinez-Zamora, Creus et al. 2011).  This is in 
contrast to studies that found lower levels of TAFIa or a higher frequency of SNPs 
associated with lower TAFIag levels, in women with miscarriage (Folkeringa, 
Korteweg et al. 2009; Masini, Ticconi et al. 2009; Pruner, Djordjevic et al. 2010; 
Legnani, Bovara et al. 2012).    
 
Recent RCTs have not been able to demonstrate a clear benefit in the use of low 
molecular weight heparin or low dose aspirin to prevent unexplained RM (Laskin, 
Spitzer et al. 2009; Clark, Walker et al. 2010; Kaandorp, Goddijn et al. 2010).  This 
would imply that fibrinolysis is not critical to implantation.  However, heparin can not 
stimulate fibrinolysis through TAFI dependant mechanisms (Colucci, Pentimone et al. 
2002) and chronic high doses of 650mg 12 hourly are required to clot lysis 
susceptibility (bjornsson, Schneider et al. 1989) .  Thus it is reasonable to conclude that 
TAFIs contribution to enhanced fibrinolysis has a role in the pathophysiology of early 
pregnancy loss. 
 
In conclusion, there are contradictory reports of TAFI levels in women with early 
reproductive failure.  This is compounded by the fact that different definition of 
recurrent miscarriage are used in addition to different methods of quantifying TAFI.  
Further large multicentre studies are warranted to clarify TAFI’s role in RM.  
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2.5 Pre eclampsia 
Pre eclampsia (PET) is a multisystem disorder of pregnancy which affects 2-8% of all 
pregnancies (Ismail and Higgins 2011). It is a major cause of maternal and fetal 
morbidity and mortality.  In the UK, PET and eclampsia continue to be one of the 
leading direct causes of maternal death with a rate of 0.85/100,000 maternities between 
2003 and 2005 (Cantwell, Clutton-Brock et al. 2011). Worldwide, 10-15% of all 
maternal deaths are a direct result of PET or eclampsia (Duley 2009). Infants born of 
pre-eclamptic mothers are five times more likely to die (Lain and Roberts 2002).   
It is a systemic syndrome resulting from inadequate trophoblastic invasion of the spiral 
arteries during placentation.  This leads to widespread maternal endothelial dysfunction 
resulting in subsequent hypertension, proteinuria and systemic manifestations of PET.  
When left untreated, PET can result in severe maternal complications including 
eclampsia, stroke, renal failure, pulmonary oedema and liver capsule rupture all of 
which can be fatal (Mol 2016).  PET can also affects the fetus as a result of intrauterine 
growth restriction (IUGR) and premature delivery.  Offspring of mothers with PET are 
at increased risk of cerebral palsy and respiratory distress as a consequence of being 
small for gestational age and being delivered prematurely, either iatrogenicaly or 
spontaneously (Hansen AR 2010; Strand KM 2013).  In addition to its immediate 
effects, PET can also result in long term consequences including:  decreased health 
related quality of life; increased post partum depression and increased maternal 
cardiovascular health risks (Blom EA 2010; Cusimano MC 2014; Prick BW 2015) 
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2.5.1 	Definition	of	PET:	
The International Society for the Study of Hypertension in Pregnancy (ISSHP) changed 
the diagnostic criteria for PET in 2014 to de-novo hypertension occurring after 20 
weeks gestation associated with either proteinuria of greater than 300mg/ day; any other 
maternal organ dysfunction (including renal or liver compromise, and haematological 
or neurological complications) or placental insufficiency (Tranquilli AL 2014).   
As proteinuria is no longer essential to diagnose PET, proteinuric and non-proteinuric 
PET are categorised separately.    
Clinically, hypertension is defined as greater than or equal to 140 mmHg systolic and/or 
90 mmHg diastolic measured on two occasions at least four hours apart after 20 weeks 
gestation (Roberts and Gammill 2005; (NICE) 2011).  PET superimposed on pre-
existing essential hypertension can be diagnosed if a woman develops significant 
proteinuria, organ dysfunction or uteroplacental insufficiency after 20 weeks (Mol 
2016).  Significant proteinuria is defined as a protein concentration of ≥30 mg (≥ 1+ on 
urine dipstick) present in a minimum of two urine samples taken at least 4-6 hours but 
no more than seven days apart.   
 
2.5.1.2 Definition of Severe PET 
The National Institute for Health and Care Excellence (NICE) define severe PET as 
severe hypertension (a systolic blood pressure of greater or equal to 160 mmHg and/ or 
a diastolic blood pressure of greater than or equal to 110mmHg) with or without 
symptoms and/ or deranged biochemical or haematological indices ((NICE) 2011). 
The American College of Obstetrics and Gynaecology  (ACOG) consider PET to be 
severe in women with any of the features listed in Table 1.  Although the ACOG’s 
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definition of severe PET is useful to stratify patients, it does not address superimposed 
PET.  This can develop in the context of pre-existing maternal disease and is a situation 
frequently encountered in clinical practice. The ISSHP have overcome this issue by 
further catergorising the hypertensive disorders of pregnancy into chronic hypertension 
(noted prior to 20 weeks gestation), Gestational hypertension (hypertension after 20 
weeks with no associated proteinuria) and PET (hypertension after 20 weeks associated 
with proteinuria (Tranquilli AL 2014).   
 
2.5.1.3 Early and late onset PET 
The outcome of PET has been shown to vary with the timing of onset of the disease 
(Vatten LJ 2004).  It has been proposed that there are different pathophysiological 
processes underlying early onset PET (prior to 34 weeks) and late onset PET (after 34 
weeks gestation) (Raymond D 2011).  Early onset disease tends to be more severe and 
causes higher levels of maternal morbidity and offspring are more likely to have lower 
birth weights (Vatten LJ 2004).  Adverse maternal outcomes are recorded in 10% of 
women with PET, with the risk increasing to 15% with early onset disease (von 
Dadelszen P 2011). 
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Table 2: ACOG Criteria for Severe PET 
New onset hypertension (blood pressure ≥ 140/90) in a previously normotensive woman after 
20 weeks gestation with a urinary protein of 0.3g or more in 24 hours with one or more of 
the following features 
 	
• Blood	Pressure:	Systolic	BP	≥	160	mmHg	and	/	or	Diastolic	BP	≥	110	mmHg	measured	6	hours	apart	with	the	patient	on	bed	rest	
• ≥	 5g	 proteinuria	 in	 24	 hours	 or	 3+	 or	 greater	 on	 two	 random	 urine	 dips	performed	at	least	4	hours	apart	
• Urine	output	of	less	than	500ml	in	24	hours	
• Headaches	or	visual	disturbances	
• Right	upper	quadrant	or	epigastric	pain	
• Deranged	liver	function	tests	
• Thrombocytopenia	
• Evidence	of	fetal	growth	restriction	
 
 
2.5.2 Maternal	morbidity	and	mortality		
PET represents one of the leading causes of maternal mortality both in the UK and 
worldwide.  PET is currently the fifth most common cause of direct maternal death (a 
death directly due to a complication of pregnancy) and account for 8.7% of direct deaths 
between 2011-2013 (Knight M 2015).  In the developing world, the incidence of PET 
is seven fold higher than in developed countries and accounts for 12% of direct maternal 
deaths: 63 000 women died from the disease in 2000 (Centre for Maternal and Child 
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Enquiries) ((CMACE) 2011).  PET also contributes to maternal morbidity, accounting 
for one third of significant morbidity (Waterstone M 2001) with 5% of sufferers 
requiring admission to intensive care (Tuffnell DJ 2005).   
 
2.5.3 Risk Factors  
Risk factors for PET include a prior history of the disease (particularly those women 
who had early onset PET) (Barton and Sibai 2008) and a family history of PET in a 
first degree relative which increases the risk of severe PET by up to fourfold (Carr, 
Epplein et al. 2005). A history of PET in the paternal grandmother also confers an 
increased risk (Esplin, Fausett et al. 2001).  
Conversely, smoking decreases the risk of PET (England, Levine et al. 2002) as does a 
previous miscarriage with the same partner and a high fruit intake (North RA 2011).  
Moderate risk factors include maternal age over 40; body mass index greater than 35; 
polycystic ovarian syndrome and a pregnancy interval of longer than 10 years ((NICE) 
2011; Roos N 2011).   Unfortunately, these risk factors only predict 30% of women 
who become pre-eclamptic (Leslie K 2011).   
 
2.5.3.1 Parity and Paternity 
The disease most commonly occurs in healthy nulliparous women in whom the 
incidence has been reported to be 7.5% (Young, Levine et al. 2010), making nulliparous 
women three times more likely to develop the disease than parous women (Duckitt and 
Harrington 2005). However, a change in paternity or a prolonged interval between 
pregnancies puts multiparous women at similar risk of PET to primiparous women 
(Tubbergen, Lachmeijer et al. 1999).  
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There is a higher incidence of PET in women with limited exposure to paternal sperm 
prior to the index pregnancy.  A previous child or a pregnancy loss with the same 
partner decreases the risk of PET.  However, the protective effect of a previous 
pregnancy is lost with a new partner (Broughton-Pipkin F 1994).  Men who have 
fathered previous pregnancies complicated by PET are twice as likely to father a pre-
eclamptic pregnancy in a different woman, regardless of their parity (Lie RT 1998). 
 
2.5.3.2 Maternal Age 
Extremes of maternal age are frequently attributed as a risk factor for the development 
of PET.  It has been suggested that younger women are at greater risk due to their 
limited exposure to sperm prior to their pregnancy.  However, Duckitt at al reported 
that women under the age of 17 were not at a significantly increased risk of PET 
(Duckitt and Harrington 2005).  In contrast, maternal age over 40 years is a widely 
accepted risk factor PET, irrespective of parity (Broughton-Pipkin F 1994; (NICE) 
2011).   
 
2.5.3.3 Ethnicity 
There are established links between ethnicity and PET, with black women at increased 
risk and Asian women at lower risk compared to the Caucasian population (Caughey 
AB 2005).  Black race also increases the likelihood of recurrence of PET in future 
pregnancies (Wright D 2012).   
 
2.5.3.4 Medical Co-morbidities 
Pre-existent maternal co-morbidities can also act as risk factors for PET.  These include: 
hypertension; diabetes mellitus; autoimmune disorders including systemic lupus 
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erythematosus and antiphospholipid syndrome; chronic renal disease and 
hypercoaguable states (Duckitt and Harrington 2005; Barton and Sibai 2008).  The 
common theme connecting these conditions is their pathological effect on endothelium 
and increased systemic inflammation.   
 
 
Table 3: Medical Conditions associated with PET 
 
 
Condition 
 
Increase in PET risk 
 
Reference 
 
Diabetes Mellitus 
 
 15-18% 
 
((NICE) 2011) 
 
Thrombophilia 
 
Five fold increase 
 
(Kingdom J 2011) 
 
Chronic Renal disease  
 
Three fold increase 
 
(Vellanki 2013) 
 
Systemic Lupus Erythematosus 
 
Two fold increase 
 
(Paez MC 2013) 
 
 
2.5.3.5 Increased placental mass 
Conditions which increase placental mass including: multiple gestation (Duckitt and 
Harrington 2005; Bdolah, Lam et al. 2008) and hydatiform mole (Koga, Osuga et al. 
2010) have been reported as risk factors for PET.  It has been suggested that increased 
placental mass induces a greater degree of inflammation during the first trimester 
(Redman, Sacks et al. 1999).  A primigravidae with a twin pregnancy has a five fold 
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increased risk of PET and a multiparous woman has a 10 fold increased risk regardless 
of her parity, compared to a primigravidae with a singleton pregnancy (Macgillivray I 
1988). 
   
2.5.3.6 Obesity 
There is a clear link between obesity and PET which has been confirmed in studies 
controlled for other risk factors (O'Brien TE 2003).  For every 5-7 kg/m2 increase in 
body mass index (BMI) the incidence of PET doubles (O'Brien TE 2003).  Dekker et 
al postulated several possible explanations for the link between obesity and PET 
including the hyperdynamic circulation and dyslipidaemia seen in obesity, cytokeine- 
mediated oxidative stress and hyperinsulinaemia leading to increased sympathetic 
activation and increased tubular sodium desorption (Dekker G 2001).   
 
2.5.3.7 Assisted Conception 
Generally, women seeking fertility treatment are older, have a higher BMI and more 
likely to have significant co-morbidities or underlying conditions such as polycystic 
ovarian syndrome.  Thus, the cohort is at increased risk of developing PET.  Assisted 
reproductive techniques are also an independent risk factor for PET.  Egg, semen and 
embryo donation can affect the fetal-maternal immune interaction.  Additionally, 
assisted reproductive techniques increase the chance of a multiple conception, an 
independent risk factor for PET (Sibai, Dekker et al. 2005) 
 
2.5.4 Cardiovascular Risk after PET 
There is overwhelming evidence in the literature that demonstrates that women with 
PET are at increased risk of developing cardiovascular disease in later life (Epstein 
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1964; Sattar N 1997; McDonald SD 2008; Doyle LW 2009; Kvehaugen AS 2011; 
Cusimano MC 2014) and until very recently this patient group had not been offered 
preventative measures.   Women who have hypertensive disorders during pregnancy 
demonstrate increased cardiovascular risk as early as two years after delivery: 30% of 
women who have PET at term have chronic hypertension and 25% will have metabolic 
syndrome  (Hermes W 2013; Veerbeek JH 2015).  This then predisposes to vascular 
endothelial dysfunction and may be the underlying mechanism of increased 
cardiovascular risk.  Alternatively, it may be that pregnancy reveals a subclinical 
condition that re-emerges at a later time. Patient education provides (them with the) 
motivation to modify their lifestyle through maintaining a healthy BMI and smoking 
cessation which can reduce their cardiovascular risk by 4-13% (Berks D 2013).  It also 
enables clinicians to monitor at risk women.   
 
2.5.5 Clinical features: 
The spectrum of presentation and lack of a reliable diagnostic test can make diagnosing 
PET challenging.  The majority of women are asymptomatic and are diagnosed due to 
routine antenatal screening.  The cardinal features of PET are a systolic blood pressure 
(SBP) ≥140 mmHg or a diastolic blood pressure (DBP) ≥90 mmHg associated with 
significant proteinuria (>0.3g in 24 hours).  However, these criteria are unhelpful in 
atypical presentations or PET superimposed on chronic hypertension or renal disease.  
Furthermore, up to 20% of women present atypically with little or no proteinuria (Sibai, 
Ramadan et al. 1993). Typically, PET is classified into mild or severe presentations as 
they require different management.  Eclampsia, is defined as a convulsive episode or 
other signs of altered consciousness and complicates up to 2% of cases (Altman, Carroli 
et al. 2002). Typically, eclampsia is superimposed on PET.  However, 20% of women 
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with eclampsia do not have associated proteinuria (Noraihan, Sharda et al. 2005) and 
33% present postpartum with no prior signs or symptoms of PET (Sibai 2005). Another 
manifestation of severe PET is Haemolysis, elevated liver enzymes and low platelet 
(HELLP) syndrome.  The onset of HELLP is frequently acute and one in three cases 
present prior to 28 weeks gestation (Habli M 2009).   
PET can also affect the fetus with severe PET resulting in: IUGR, oligo hydramnios, 
iatrogenic premature delivery and an increased risk of perinatal death (Sibai, Dekker et 
al. 2005).  The pathogenesis of these complications remains unconfirmed, but are 
thought to be a result of vascular abnormalities in the utero-placental unit which cause 
placental abruption and infarction (Young, Levine et al. 2010).  
In addition to its acute complications, PET is associated with a twofold increased risk 
of premature maternal cardiovascular and cerebrovascular disease (Young, Levine et 
al. 2010).  Women with PET are ten times more likely to develop chronic hypertension 
within seven years of their pregnancy compared women who have had uncomplicated 
pregnancies (Young, Levine et al. 2010).  The offspring of pre-eclamptic pregnancies 
also have an increased risk of cardiovascular disease and metabolic syndrome in later 
life (Barker, Martyn et al. 1993; Eriksson, Forsen et al. 2001; Osmond, Kajantie et al. 
2007). 
 
2.5.5.1 Signs and symptoms: 
Clinicians routinely enquire about symptoms of PET including headache, visual 
disturbances and right upper quadrant or epigastric pain.  Unfortunately, no symptoms 
adequately predict adverse maternal outcomes (Thangaratinam S 2011).  Similarly a 
mean arterial pressure of greater than 140 mmHg or a blood pressure of greater than 
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170/110 mmHg have limited value in the prediction of eclampsia, placental abruption, 
or renal, neurological or hepatic impairment (Thangaratinam S 2011).    
 
2.5.6 Pathogenisis of PET: 
In normal pregnancy, extravillous cytotrophoblasts originating from the fetus invade 
the uterine spiral arteries.  The fetal cytotrophoblast replaces the endothelium of the 
maternal spiral arteries. This converts the spiral arteries from small calibre high 
resistance vessels into low resistance, high capacity vessels to facilitate the increased 
blood flow and oxygenation required by the fetus.  In PET, there is inadequate invasion 
of the myometrium by the cytotrophoblast, which only penetrates as far as the decidua 
so the myometrial segments of the spiral arteries remain high resistance vessels which 
results in fetal hypoperfusion.  This is followed by widespread maternal endothelial 
dysfunction which produces the clinical symptoms of the disease.  However, the cause 
of placental dysregulation remains unknown.  Previous research has postulated that 
hypoxia, inflammation, antiangiogenic proteins, alterations of the renin- aldosterone- 
angiotensin II pathway, oxidative stress, and genetic factors may all contribute to the 
pathogenisis of PET (Young, Levine et al. 2010).  
 
2.5.6.1 Role	of	the	placenta:	
PET cannot occur without the placenta, whereas the presence of the fetus is irrelevant.  
Cases of PET have been reported in women with hydatiform mole (where there is no 
fetus present).  Furthermore, the condition was seen to remit after curettage to remove 
the abnormal placental tissue (Koga, Osuga et al. 2010).  Postpartum eclampsia can 
occur as a result of retained placental fragments and again, symptoms resolve after 
uterine curettage (Matsuo, Kooshesh et al. 2007). Finally, case reports of PET 
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complicating abdominal pregnancy report that delivery of the fetus alone did not lead 
to resolution of PET.  This does not occur until the placenta was delivered (Shembrey 
and Noble 1995).  
Severe PET is associated with placental hypoperfusion and ischaemia.  Acute atherosis, 
and diffuse vascular obstruction resulting from fibrin deposition, intimal thickening and 
necrosis and atherosclerosis have all been found in placentas of women who suffered 
from severe PET (Young, Levine et al. 2010). Placental infarcts due to occlusion of the 
spiral arteries are another common pathological feature of severe PET (Salafia, 
Pezzullo et al. 1998). The severity of placental pathology has been shown to correlate 
with the severity of the disease (Salafia, Pezzullo et al. 1998).  A decrease in 
uteroplacental perfusion can be detected by uterine artery Doppler ultrasound and 
frequently precedes the manifestation of clinical symptoms (North, Ferrier et al. 1994).  
 
 
2.5.6.2 Vascular	development	of	the	placenta:	
During normal placentation, fetal cytotrophoblasts undergo a process called 
pseudovasculogenesis in order to function as endothelial cells.  This involves the down 
regulation of adhesion molecules that are typically expressed by the cytotrophoblast as 
they adopt a vascular phenotype (Zhou, Fisher et al. 1997). In pre-eclamptic patients, 
the cytotrophoblast adhesion molecules fail to convert to endothelial cell surface 
adhesion molecules, which inhibits the invasion of the myometrial spiral arterioles 
(Zhou, Damsky et al. 1997).  
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2.5.6.3 Altered angiogenic balance: 
Angiogenic factors including vascular endothelial growth factor (VEGF) and placental 
growth factor (PlGF) and their receptors (VEGFR 1, VEGFR 2, Tie 1 and Tie 2) are 
essential for normal placental vascular development and are expressed by the placenta 
in the first trimester.  Alterations in the regulation or signalling of angiogenic factors 
or their receptors during early placentation may result in inadequate endovascular 
invasion.    Immunohistochemistry has shown that the expression of VEGF and its 
receptors is altered in PET (Zhou, McMaster et al. 2002).  
VEGF acts to stabilise endothelial cells in mature blood vessels and its actions are 
particularly important in the liver, kidneys and brain (Maynard, Min et al. 2003; 
Maharaj, Walshe et al. 2008). FMS-like tyrosine kinase (Flt-1) is a major VEGF 
receptor.  sFlt-1 is a truncated variant of Flt-1 which lacks its transmembrane and 
intracellular signalling domains and is secreted into the maternal circulation by 
syncitiotrophoblast cells (Nagamatsu, Fujii et al. 2004). sFlt-1 antagonises VEGF and 
PlGF by binding to their free circulating forms and thus preventing them from 
interacting with their receptors (Kendall and Thomas 1993).  
VEGF is needed for glomerular capillary repair and thus high levels are expressed by 
glomerular podocytes (Maharaj, Saint-Geniez et al. 2006).  In addition, VEGF receptors 
can be found on glomerular endothelial cells.  Deletion of the podocyte specific VEGF 
gene in mice results in glomerular endothelial damage and subsequent proteinuria and 
hypertension (Eremina, Sood et al. 2003). Anti VEGF antibodies have been infused in 
patients participating in antiangiogenic cancer trials.  Again, these patients exhibited 
hypertension, proteinuria and glomerular endothelial dysfunction (Eremina, Jefferson 
et al. 2008; Patel, Morgan et al. 2008). 
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PlGF is a potent angiogenic growth factor, which increases VEGF signalling by 
displacing VEGF from Flt-1, causing it to bind to the more active VEGFR-2 (Kendall, 
Wang et al. 1996).  PlGF increases angiogenisis in the presence of inflammation, 
ischaemia and during wound healing (Carmeliet, Moons et al. 2001; Autiero, Luttun et 
al. 2003). Abnormally low levels of PlGF have been demonstrated in women who 
develop PET, prior to the onset of clinical symptoms (Levine, Maynard et al. 2004).  
sFlt-1 decreases cytotrophoblast invasiveness in vitro and is found in low concentration 
during the first and second trimesters of normal pregnancy (Zhou, McMaster et al. 
2002). sFlt-1 levels increase in the third trimester which may be a reflection of the 
completion of angiogenic placental growth (Levine, Maynard et al. 2004). In vivo, sFlt-
1 causes endothelial dysfunction and vasoconstriction and when infused into pregnant 
rats causes proteinuria, hypertension and glomerular endothelial dysfunction (Maynard, 
Min et al. 2003). Chorionic villous sample biopsies of women who subsequently 
developed PET demonstrate altered angiogenic factors including an increased amount 
of sFlt-1 (Farina, Sekizawa et al. 2008). Not only is increased placental sFlt-1 seen prior 
to the onset of symptoms, levels are proportional to the severity of disease (Hertig, 
Berkane et al. 2004; Levine, Maynard et al. 2004; McKeeman, Ardill et al. 2004; 
Wathen, Tuutti et al. 2006).  
 
Levels of transforming growth factor β (TGFβ) and its receptor endoglin, are inversely 
proportional to cytotrophoblastic invasiveness.  In normal pregnancy, levels of TGFβ 
decrease after 9 weeks gestation.  However, this decrease in not observed in pre-
eclamptic women (Caniggia, Taylor et al. 1997), who also have higher circulating 
levels of sEng (Venkatesha, Toporsian et al. 2006).  sEng is a truncated form of 
endoglin and also acts as a TGFβ receptor and is thought to act by inhibition of 
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vasodilatation by nitric oxide (NO) (Levine, Lam et al. 2006).  Infusion of sEng into 
pregnant rats amplifies the vascular damage caused by increased sFLt-1 causing them 
to exhibit a syndrome similar to HELLP (Venkatesha, Toporsian et al. 2006).  
Interestingly, increased levels of sEng have also been found in small for gestational age 
pregnancies with no evidence of PET (Levine, Lam et al. 2006; Romero, Nien et al. 
2008). 
NO is a potent vasodilator and a downstream mediator of VEGF and PlGF.  Reduced 
levels of NO metabolites are seen in women with PET and the amount of NO inhibition 
correlates with sFLt-1 and sEng levels (Sandrim, Palei et al. 2008). 
The existing evidence of alterations in the angiogenic axis in women with PET supports 
the theory that they have a role in the disruption of cytotrophoblastic invasion which is 
characteristic of the syndrome.   
 
2.5.6.4 Placental	ischaemia	and	hypoxia	
Although placental hypoxia causes increased levels of antiangiogenic proteins, it 
remains to be seen if PET is a consequence or a result of placental ischaemia and 
hypoxia.  Hypoxia has been shown to increase levels of sFlt-1 in first trimester placental 
trophoblast cultures (Karumanchi and Bdolah 2004).  Previous animal studies have 
demonstrated that hypertension and proteinuria can be produced by limiting uterine 
artery blood flow but not HELLP or eclampsia (Granger, LaMarca et al. 2006; Makris, 
Thornton et al. 2007).  Furthermore, placental insufficiency frequently leads to 
intrauterine growth restriction unaccompanied by the syndrome of PET.  
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2.5.6.5 Maternal	endothelial	dysfunction	
The diseased placenta releases vasopressive factors into the maternal circulation of pre-
eclamptic women (Redman, Sacks et al. 1999).   Serum markers of endothelial 
dysfunction and activation including soluble tissue factor, von Willebrand factor 
antigen, fibronectin, platelet derived growth factor and endothelin are abnormally 
elevated in PET (Roberts and Lain 2002).  When normal endothelial cells are infused 
with the serum of pre-eclamptic women, endothelial cell dysfunction occurs which 
subsequently cause the manifestation of symptoms (Rodgers, Taylor et al. 1988; 
Roberts, Taylor et al. 1989). 
   
2.5.6.6 Haemodynamic	changes:	
Normal pregnancy is associated with a physiological decrease in peripheral vascular 
resistance and hence arterial blood pressure (Roberts and Gammill 2005).  In PET, 
women have a heightened sensitivity to circulating vasopressors such as angiotensin II 
(Gant, Chand et al. 1974).   This, in combination with decreased levels of vasodilators 
and impaired endothelium-dependant vasorelaxation (Khan, Belch et al. 2005), results 
in increased systemic vascular resistance and a decreased cardiac output (Easterling 
1992).  Together, these changes produce the symptom of hypertension. 
 
Angiotensin II hypersensitivity may be a result of autoantibodies which act as agonists 
for its receptors (Wallukat, Homuth et al. 1999).  These same receptor autoantibodies 
have been shown to impair trophoblastic invasion (Xia, Wen et al. 2003) and when 
recovered from the serum of women with PET and infused into mice, cause increased 
secretion and expression of sFlt-1, placental damage and PET symptoms (Zhou, Zhang 
et al. 2008).  
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2.5.6.7 Immune	changes:	
To allow the fetus to develop, the uterus becomes an immune privileged site.  
Abnormalities in the immune system may contribute to decreased trophoblastic 
invasiveness.    Women with untreated HIV are less likely to develop PET than the 
general obstetric population and their risk increases to normal levels after antiretroviral 
treatment (Mattar, Amed et al. 2004).  Furthermore, women who conceive via 
intracytoplasmic sperm injection with sperm collected via testicular biopsy are three 
times more likely to develop PET than if the sperm is acquired via ejaculation (Wang, 
Knottnerus et al. 2002).  Women who have had decreased contact to sperm due to the 
routine use of barrier contraception also have a higher PET risk (Klonoff-Cohen, Savitz 
et al. 1989).  When coupled with the fact that PET is more prevalent in nuliparous 
women, those with new partners and after a long interval between pregnancies, it 
suggests that an abnormal maternal immune response to fetal antigens may have a role 
in the pathology of PET.	
In addition to the decidual cells which form the bulk of the gravid endometrium, natural 
killer (NK) cells, macrophages and dendritic cells can also be detected.  Together they 
are the major antigen presenting cells of the uterus and act to prevent the rejection of 
fetal cells (Huang, Chen et al. 2008).  Significantly increased numbers of macrophages 
and dendritic cells are found in pre-eclamptic placentas (Lockwood, Matta et al. 2006; 
Huang, Chen et al. 2008).  This excess of immune cells stimulates the secretion of tissue 
necrosis factor-α which induces apoptosis of the extravillous cytotrophoblast 
(Genbacev, DiFederico et al. 1999).  
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2.5.6.8 Liver,	kidney	and	cerebral	changes:	
Pathological changes in these organs are consistent with widespread hypoperfusion.  
The liver and adrenals both exhibit signs of intraparenchymal haemorrhage, infarction 
and necrosis.  Characteristic changes within the glomeruli are known as glomerular 
endotheliosis.  They include loss of capillary space, vaculosiation of the endothelium 
and generalised swelling (Spargo, Mc et al. 1959).  Subendothelial fibrin deposits 
decrease the surface area of the glomeruli that can be used for filtration (Lafayette, 
Druzin et al. 1998).  Overall there is a 40% decrease in glomerular filtration rates 
(Lafayette, Druzin et al. 1998). 
Post-mortem findings in eclampsia sufferers include cerebral oedema and 
intraparenchymal haemorrhage.  The oedema is thought to result from endothelial 
dysfunction as opposed to as a direct consequence of hypertension because the amount 
of oedema is not proportional to the increase in BP.   
Although our understanding of the pathology of PET is continually advancing, the 
disease remains a leading cause of morbity and mortality, with implications for both 
future pregnancies and maternal cardiovascular health.  PET frequently presents 
atypically, mimicking other conditions, resulting in women not being treated 
appropriately as their symptoms do not meet defined clinical criteria.  Screening and 
diagnostic tests would enable the early identification, enabling clinicians to improve 
the monitoring and supportive care they provide.   
 
2.5.7 Current Screening methods for PET: 
The accurate identification of women at risk of developing PET would enable the 
implementation of interventions and intensive monitoring to prevent disease 
progression.  Unfortunately the quest for a “perfect screening method” remains elusive.  
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The following section details the various screening modalities and markers that are in 
use or being researched at present.   
   
2.5.7.1 Maternal history: 
Although risk factors revealed by maternal history only predict severe PET in 30% of 
cases, NICE recommends its use for screening ((NICE) 2011).  The Screening for 
Pregnancy Endpoints (SCOPE) study tried to stratify healthy nulliparous women into 
those at high or low risk of developing PET.  The study developed a referral framework 
based on clinical risk factors including: age; blood pressure; BMI; family history of 
PET or ischaemic heart disease; maternal birth weight; the presence of antenatal vaginal 
bleeding and notching of increased resistance index on uterine artery dopplers (North 
RA 2011).  However, the authors found that the model was only moderately predictive 
and recommended the validation of further models (North RA 2011).     
 
2.5.7.2 Blood pressure: 
Cnossen et al suggested that a mean arterial greater than 90mmHg in the second 
trimester is predictive of the onset of PET in a low risk woman with a positive 
likelihood ratio of 3.5 and a negative likelihood ratio of 0.39.  The authors also 
examined the use of systolic and /or diastolic blood pressure to predict PET.  However, 
both were poor predictors for the disease (Cnossen JS 2008).   
 
2.5.7.3 Uterine artery Doppler 
Outside of pregnancy, uterine artery Doppler waveforms consist of a rapid increase 
followed by a fall of the uterine artery velocity during systole and the narrow calibre 
high resistance spiral arteries cause notching of the velocity in early diastole.  The 
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second wave of trophoblastic invasion of the spiral arteries converts them into low 
resistance vessels to facilitate flow through the placenta.  This leads to the loss of 
diastolic notching of the uterine arteries during pregnancy.   
Due to impaired trophoblastic invasion of the spiral arteries in PET, the uterine arteries 
remain in a high resistance state.  The placental dysfunction manifests as notching of 
the uterine artery during diastole and a raised resistance index (RI) and Pulsitility index.  
RI is a marker for resistance to blood flow in the vascular bed and the PI represents 
average blood flow (Nicolaides K 2000).  Severe PET in low risk women is best 
predicted by bilateral uterine artery notching and a raised PI (Cnossen JS 2008).  In 
high risk patients, PET is best predicted using unilateral notching and a raised PI 
(Cnossen JS 2008).  Unfortunately, uterine artery dopplers have a high false positive 
rate in the prediction of PET so it is currently recommended that they are used in 
conjunction with further monitoring ((NICE) 2011).   
 
2.5.7.4 Biomarkers 
Angiogenic Factors: 
Placental ischaemia and the subsequent release of various angiogenic factors is one of 
the proposed mechanisms of PET.  The alterations in the balance of pro and anti-
angiogenic factors can be detected in the maternal circulation from the first trimester 
(Myatt L 2012).  Due to elevated sFLT-1 levels and decreased PlGF and VEGF in the 
circulation of affected women, it has been suggested that there is a higher placental 
expression of sFLT-1 in PET (Chen 2009).  Increased levels of sFLT-1 are seen in pre-
eclamptic women from the second trimester onwards (Monte 2011) and lower levels of 
VEGF and PlGF are evident  as early as the first trimester (Romero R 2008).   
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sEng is increased in the serum and placentas of women with PET, leading to the 
conclusion that sEng makes a contribution to the pathophysiology of the disease 
(Hladunewich M 2007).  Indeed, altered levels of sEng, sFLT-1 and PlGF levels 
antecede the clinical manifestations of the disease by several weeks (Chen 2009).  A 
systematic review of 32 studies investigated angiogenic factors’ potential to act as 
biomarkers to predict pre-eclampsia (Kleinrouweler C 2012). Although plasma 
concentrations of PlGF, sFLT-1 and sEng concentrations were significantly altered 
prior to 30 weeks gestation in women who developed PET, the accuracies of the four 
markers were not yet robust for use in clinical practice (Kleinrouweler C 2012).   
 
Uric Acid 
Plasma uric acid levels were linked to PET as early as 1917 (Siemons JM 1917).  Uric 
acid is produced during purine breakdown.  As gestation increases advances, there is 
increased cell turnover in the placental bed and hence uric acid concentrations rise 
progressively.  It has been suggested that uric acid concentrations are further raised in 
PET due higher rates of cell breakdown in the injured placental bed.  A systematic 
review demonstrated that uric acid is an unreliable predictor of PET (Thangaratinam S 
2006).   
 
Combination models 
As yet no single, reliable biomarker for PET has been identified.  Alberry et al explored 
the possibility of a combination of ultrasound and biomarkers to predict PET (Alberry 
M 2011).  Fetal nucleic acids circulate freely in the maternal serum as free fetal DNA 
and mRNA and higher circulating levels have been demonstrated in women with PET 
(Alberry M 2011).  Unlike free fetal DNA, mRNA has the advantage of being a sex 
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independent marker and could have a role in screening either alone or in combination 
with uterine artery Dopplers.  
 
2.5.8 Prevention of PET: 
There is no cure for PET at present.  When a woman develops the disease, clinicians 
must make a decision based on the risk-benefit ratio of prolonging the pregnancy to 
improve fetal maturity versus the risk of maternal morbidity with continuing the 
pregnancy.  Various measures have been trialled in order to prevent PET before the 
clinical syndrome develops.   
 
Aspirin: 
In PET there is reduced production of prostacyclin, a potent vasodilator and increased 
quantities of the vasoconstrictor thromboxane, which potentiates platelet aggregation 
(Briceno-Perez C 2009).  Aspirin is a cyclooxygenase (COX) inhibitor and prevents 
COX from acting as a catalyst in the conversion of arachidonic acid to thromboxane.  
This limits platelet aggregation in the placental bed.  A Cochrane review of 59 trials 
demonstrated a 17% reduction in PET.  Women stratified as high risk for developing 
PET had a higher risk reduction compared to women at moderate risk (Duley, 
Henderson-Smart et al. 2007).  NICE advice that low dose aspirin be given to women 
at high risk of PET from 12 weeks gestation until delivery ((NICE) 2011).  NICE define 
women at high risk as the following: those who suffer from chronic hypertension or 
have previously suffered gestational hypertension in their last pregnancy; those with 
chronic renal disease or those with autoimmune conditions such as Antiphospholipid 
syndrome, systemic Lupus erythematosus or diabetes mellitus.   
Heparin:  
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As previously detailed, thrombosis, infarction and necrosis can be seen in the placentas 
of women who develop PET.  Prior researchers have investigated the use of heparin to 
prevent PET (Kingdom J 2011).  Heparin has several modes of action.  Firstly, it 
promotes the proliferation of cytotrophoblast by facilitating FGFs to enhance mitotic 
signalling.  The enhanhanced production of cytotrophoblast maintains a healthy outer 
syncytiotrophoblast which interfaces with maternal blood.  Secondly, heparin 
suppresses complement activation, a feature which is enhanced in women that develop 
PET.  Despite these actions, heparin has not been shown to cause a significant reduction 
in the development of PET (Kingdom J 2011).   
 
Vitamin D 
Vitamin D is a fat-soluble protein with anti inflammatory and immune modulatory 
effects.  PET has been linked to vitamin D deficiency (Tabesh M 2013).  It was 
postulated that the enhanced inflammatory response and importance of immune 
modulators could explain the link.  A Cochrane review investigated the effect of 
vitamin D supplementation on pregnancy outcomes (De-Regil 2012) but of the six trials 
analysed in the review only one had reducing PET as a primary outcome measure.  
Women who received 1200 IU vitamin D were not less likely to develop PET (De-
Regil 2012).  Further studies are needed to determine if different dosages of vitamin D 
have an effect on PET risk and to determine the safety of supplementation.   
 
2.5.9 Haemostasis in Preeclampsia 
At present it is not fully understood how reduced placenta perfusion due to failed 
vascular remodelling progresses to the multi-system syndrome of PET, or why it only 
occurs in a proportion of women after the initial insult.  In addition to the evidence of 
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multi organ hypoperfusion, previously mentioned evidence of widespread 
microthrombi deposition is also present in women who die from eclampsia (Roberts 
and Lain 2002).   Abnormalities of haemostasis which result in, or cause excess 
uteroplacental thrombosis, may contribute to the pathophysiology of PET. 
 
2.5.9.1 Haemostasis in the systemic circulation 
Procoagulants: 
Women with PET display exaggerated coagulation activation compared to the general 
obstetric population with coagulation markers including TAT (a surrogate marker of 
thrombin generation) (Chaiworapongsa, Yoshimatsu et al. 2002), TF (Rousseau, Favier 
et al. 2009), FVIII consumption (Thornton and Bonnar 1977) and fibrinogen (Bonnar, 
McNicol et al. 1971; Halligan, Bonnar et al. 1994) showing additional increases.  In 
addition, women with PET demonstrate increased endogenous thrombin potential 
(ETP- a global assay of haemostasis) when compared with normotensive pregnant 
controls (Rafik Hamad, Curvers et al. 2009) who in turn have a higher ETP than non-
pregnant women (Rosenkranz, Hiden et al. 2008).  Interestingly in pre-eclamptic 
women, enhanced ETP is associated with increased platelet activation which is not 
present in the normotensive population.  This may account for the benefits of treatment 
with aspirin in PET (a 17% reduction in the risk of developing PET; a 14% reduction 
in neonatal mortality and 8% lower risk of premature delivery) (Duley, Henderson-
Smart et al. 2007).  
Anticoagulants: 
Contradictory evidence is available regarding the changes in antithrombin levels in 
normal pregnancy.  Several studies have found that antithrombin levels remain 
unchanged during (Stirling, Woolf et al. 1984; Rosenkranz, Hiden et al. 2008) and 
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others have demonstrated decreased levels in the third trimester and postpartum period 
(Wickstrom, Edelstam et al. 2004; Tanjung, Siddik et al. 2005).  Significantly decreased 
levels of AT are seen in women with PET compared with controls (Tanjung, Siddik et 
al. 2005) which may be a reflection of increased consumption.       
An additional key regulator of thrombin generation is tissue factor pathway inhibitor 
(TFPI).  Two types exist: TFPI-1 which is found in the maternal and fetal circulations 
and TFPI-2 which is mainly found in the placenta.  In normal pregnancy, concentrations 
of TFPI-2 gradually increase with gestation to peak at 36 weeks, after which they 
decline (Chand, Foster et al. 2005).  Women with PET have significantly higher 
concentrations of both TF and TFPI (Abdel Gader, Al-Mishari et al. 2006; Erez, 
Romero et al. 2008).  However, the TF:TFPI ratio is lower than in the normal 
population, suggesting that the increase TFPI levels are insufficient to counteract the 
increase in TF (Erez, Romero et al. 2008).   
 
2.5.9.2 Fibrinolysis in PET   
Fibrinolysis is dependent upon the balance of basal levels of tPA, PAI-1 and tPA 
released from the endothelium as a reaction to vascular injury or thrombus formation 
(Oliver, Webb et al. 2005).  By the third trimester, there is a 4-5 fold increase in PAI-1 
in the normal pregnant population (Coolman, de Groot et al. 2006; Robb, Mills et al. 
2009).  PAI-1 inhibits the release of endothelial tPA, thus the increased levels of PAI-
1 in normal pregnancy further reduce tPA levels (Robb, Mills et al. 2009).  PAI-2 is 
produced by the placenta, accordingly levels increase with gestation as the placental 
mass grows (Reith, Booth et al. 1993).   
When affected by PET, women exhibit an additional increase in PAI-1 compared to 
normotensive pregnant controls which precedes the onset of clinical symptoms and 
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evidence of placental dysfunction detected as uterine artery Doppler notching (Hunt, 
Missfelder-Lobos et al. 2009).  Contrastingly, PAI-2 levels in PET are significantly 
lower than in normal pregnancy, most likely due to placental dysfunction (Tanjung, 
Siddik et al. 2005).   
 
 
2.5.9.3 Uteroplacental circulation 
As previously mentioned, there are three distinct haemostatic challenges in pregnancy: 
i) implantation, where trophoblast invades the maternal decidual vessels; ii) the 
antenatal period during which the blood must remain fluid enough to flow readily 
through the low resistance system of the uteroplacental unit and finally; iii) delivery 
where coagulation has to occur quickly in order to prevent life threatening haemorrhage 
from the placental bed.  TF appears to be the key procoagulant during implantation.  It 
is produced by maternal human endometrial stromal cells (HESC) (Lockwood, Krikun 
et al. 2000) which enable the trophoblastic invasion of the decidual vessels to occur 
without massive haemorrhage occurring.  The overall haemostatic balance of 
implantation is maintained by TF, TFPI-1 produced by endothelial cells and TFPI-2 
released from the placental trophoblast (Dusse, Carvalho et al. 2006).  This is supported 
by the findings of animal studies where the TF or TFPI genes are inactivated in mice 
result in miscarriage (Parry and Mackman 2000; Pedersen, Holscher et al. 2005).   
 
In PET placental TF mRNA expression is increased (Estelles, Gilabert et al. 1998; 
Dusse, Carvalho et al. 2006), but TFPI mRNA expression and total TFPI concentrations 
are lower than the general obstetric population (Aharon, Lanir et al. 2005; Dusse, 
Carvalho et al. 2006). Thus, although both coagulation and fibrinolysis are activated in 
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the uteroplacental circulations of both normal and pre-eclamptic women, PET is 
associated with notable abnormalities.    
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Chapter 3  
 
LABORATORY METHOD  
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3.0 TAFI Antigen and Activity assays 
There are three main methods to determine TAFI plasma concentrations: 
immunological, activity based and functional assays.  When designing a study protocol, 
it is particularly important to consider the advantages and drawbacks of each method.  
Many previous studies have used assays that were inadequately validated, making 
interpretation of their results difficult.   
 
3.1 Immunological  assays: 
Historically, this has been the most commonly used method of measuring TAFI levels.  
It has the advantages of: being relatively quick and easy to perform using commercially 
available kits; the zymogen is measured directly and does not require any preliminary 
activation and there is no interference from carboxypeptidase N (CPN).  Furthermore, 
as TAFI plasma concentrations are well below the Km for activation by the thrombin-
thrombomodulin complex the amount of TAFIa formed will be dependent upon the 
TAFI Ag concentration.   
However, immunoassays have two major drawbacks.  Prior studies have reported a 
degree of genetic control of TAFI Ag plasma concentrations (Chetaille, Alessi et al. 
2000; Henry, Aubert et al. 2001). A single nucleotide polymorphism (SNP) at position 
1040 results in the substitution of Thr-to-Ile at position 325 in the protein.  The Ile325 
TAFI variant has a much longer half life than the Thr325 variant (15 minutes compared 
to 8-10 minutes) (Boffa, Bell et al. 2000; Schneider, Boffa et al. 2002).  The 
immunoreactivity of the TAFI isoform is strongly affected by this SNP and its resultant 
substitution (Gils, Alessi et al. 2003).  Gils et al optimised two ELISAs: the first was 
not affected by the 325 genotype but the second demonstrated no reaction with the 
Ile325 geneotype (Gils, Alessi et al. 2003).  One commercially available ELISA kit, 
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which uses two monoclonal antibodies, has been shown to be free of genotype-based 
bias.  The various commercially available ELISA kits yield notably different results.  
Thus, accurate comparison of data generated by different studies will not be possible 
until an international standard for TAFI Ag is defined. 
Secondly, although plasma TAFI is predominantly in the form of TAFI Ag, it also exists 
in various other states including TAFI Ag bound to plasminogen and inactive TAFI 
fragments.  The antibodies in the ELISA kit can have different reactivities to these 
various forms (Gils, Alessi et al. 2003).  Again, this can produce different results for 
the same sample when different monoclonal antibodies are used in the ELISA kits.   
Normal pooled plasma is used to calibrate the ELISA assays.  The dilutional profile of 
the pooled plasma can also be affected by genotype frequencies, i.e. it can be more 
similar to Thr325 than Ile325 genotype pooled plasma or vice versa. This can produce 
further discrepancies in the ELISA results which may account for the wide variation of 
the reported mean plasma TAFI Ag concentrations (Guimaraes, van Tilburg et al. 
2004).  This further emphasises the necessity of meticulous standardisation of the 
assays used in further studies.      
Other immunological assays including Rocket immunoelectrophoresis have been 
reported.  This method has the advantage of being insensitive to genotype bias.  
However, the method is laborious, making it impractical to use in large studies such as 
ours.   
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3.2 Enzymological assays: 
These assays are based on the principal that when activated TAFIa can cleave the C-
terminal lysine or arginine from various protein and peptide substrates upon the 
addition of thrombin/ thrombomodulin to the plasma sample.  Hippuryl-arginine/ lysine 
is a peptide substrate that is converted to hippuric acid by TAFIa. This conversion can 
be monitored by measuring the change in the absorbance. 
The main benefit of enzymological assays is that only the functionally active TAFIa is 
quantified and the various fragments of TAFI Ag that have undergone proteolytic 
cleavage or conformational alterations are not included.  Furthermore, both the Thr325 
and Ile325 isoforms of TAFI Ag have comparable activation kinetics and once activated 
both have similar carboxypeptidase activity toward the synthetic substrates used in the 
assay (Zhao, Morser et al. 1998; Schneider, Boffa et al. 2002). Due to the extra step of 
activation of TAFI Ag required, this type of assay is more time consuming than 
immunoassays and requires a robustly standardised activation protocol (Bajzar, Morser 
et al. 1996; Schatteman, Goossens et al. 2000). Furthermore, in some commercially 
available assay kits, the substrates used are not selective for TAFI.  Therefore, a small 
proportion of the lysine/ arginine residues produced will be a result of the intrinsic 
activity of other carboxypeptidases including CPN.   
A further drawback in activity-based assay is that they are affected by the intrinsic 
instability of TAFIa and its different isoforms.  Placing the samples on ice can help 
stabilise TAFIa after activation by arresting the conformational change that renders the 
protein inactive (Schneider, Boffa et al. 2002). Excess substrate can also stabilise 
TAFIa (Willemse and Hendriks 2006). However, if due to the amount of TAFIa 
produced, all the substrate is converted, the TAFIa will begin to decay and thus TAFI 
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activity underestimated.  Thus, large quantities of substrate are added to overcome this 
difficulty.   
 
3.3 Functional Assays 
Global assays of haemostasis evaluate the net coagulation/ fibrinolytic capacity.  
Although they are unable to detect specific haemostatic abnormalities, they are often of 
more practical value when assessing thrombotic/-bleeding risk in clinical practice.  
Advances in the continuous measurement of thrombin generation in plasma have been 
used in clinical coagulation research to further the understanding of coagulation in 
neonates (Cvirn, Gallistl et al. 1999; Cvirn, Gallistl et al. 2003).  However, thrombin 
generation cannot be used to assess fibrinolysis.  Many global assays of haemostasis 
have been developed, but the two most frequently used in clinical practice are the 
thromboelastogram and euglobin clot lysis time (CLT). 
CLT measures plasma fibrinolytic activity and was originally described in 1948 
(Macfarlane and Biggs 1948).  It measures changes in optical density of the recalcifed 
euglobulin fraction of plasma over a two hour period.  Prior studies have 
demonstrated that CLT is not prolonged by short term storage of frozen samples 
(Prisco, Paniccia et al. 1994). 
Guimaraes et al described an assays designed to assess the total amount of functional 
TAFI in plasma samples based on clot lysis times (Guimaraes, van Tilburg et al. 2004). 
Immunodepletion is used to produce TAFI deficient plasma which is then added to the 
plasma sample undergoing testing.  The mixture is then allowed to clot in the presence 
of thrombomodulin which activates TAFI.  Subsequent clot lysis is then quantified by 
measuring the turbidity of the mixture in a microplate reader.  Duplicates of each 
sample are run simultaneously, to which potato tuber carboxypeptidase inhibitor 
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(PTCI) (a TAFI specific inhibitor) have been added.  This allows the quantification of 
the contribution of TAFIa to the retardation of clot lysis.  This assay is sensitive to 
plasma antigen levels and to which isoform is present (Guimaraes, van Tilburg et al. 
2004).   
To overcome to limitations of each of the above methods, in the following studies all 
three assays were performed for each of the samples collected.  This enabled 
quantification of TAFI zymogen levels, TAFI’s activity and its contribution to global 
haemostasis.   
 
3.4 Methods used in this thesis: 
3.4.1 TAFI Activity (TAFI Actichrome®) 
The Actichrome kit (American Diagnostica) is a commercially available chromogenic 
assay used to determine the concentration of activateable TAFI in plasma samples.  The 
assay is dependent upon the activation of TAFI by the thrombin-thrombomodulin 
complex.  The TAFIa that forms then reacts with a chromogenic substrate which is 
highly specific for TAFIa.   
The initial step of the assay is to incubate plasma samples (which have been diluted 25-
fold in the assay buffer) with the TAFI activation reagent in a microtitre plate well.  The 
thrombin-thrombomodulin complex in the activation reagent converts TAFI into 
TAFIa.  An Activation Stop reagent is then added to the plate to arrest TAFI activation.  
Finally the TAFI Developer, containing the TAFI specific substrate is added to the well 
and an enzymatic reaction ensues.  This reaction is then terminated by the addition of 
sulphuric acid so the optical density of the solution at 405nm can be quantified.  A plain 
diluted plasma sample which has not been incubated with the TAFI activation reagent 
is run in parallel as a control.  The difference in optical density between the activated 
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plasma sample and the control, representing the amount of TAFI activity in the sample, 
can then be calculated.   
Using the TAFI standard included in the kit, a calibration curve was created.  The 
absorbances of the samples were then compared to the calibration curve.   
 
 
3.4.2 TAFI Antigen Concentration (ELISA) 
TAFI Ag was quantified using a commercially available kit (Zymutest TAFI Ag, 
Hyphen Biomedical) for a sandwich ELISA specific for human TAFI Ag.  The pre 
diluted plasma samples were placed into microwells pre-coated with a monoclonal 
antibody specific for human TAFI.  The TAFI Ag present in the plasma sample binds 
to the monoclonal antibody. The wells are then washed and the immunoconjugate 
added to the plasma samples in the wells.  The immunoconjugate consists of a goat 
polyclonal antibody coupled with horse radish peroxidise.  It reacts with the TAFI Ag 
in the wells.  After the wells have again been washed, the peroxidise substrate 
(tetramethylbenzidine (TMB) and hydrogen peroxide) is added to the wells which turn 
blue.  Finally, the reaction is stopped with sulphuric acid and the wells turn yellow.  
The colour density is proportional to the plasma concentration of TAFI Ag.  
 
 
3.4.3 Clot Lysis Time: 
This is a functional assay of TAFI, which works on the principal that TAFIa will retard 
clot lysis mediated by tPA in a plasma sample.  Test plasma samples are mixed with 
reagents listed in table 1 and is then left to incubate, so clot formation can occur in 
conjunction with TAFI activation by thrombomodulin.  Subsequent clot lysis as a result 
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of TAFI activation is quantified using a microplate reader which measures changes in 
turbidity.  A control assay (using PTCI to specifically inhibit TAFIa) is run in parallel.  
This allows for the quantification of the contribution of TAFI to the retardation of clot 
lysis.   
 
 
 
 
 
Table 4: Materials required for TAFI antigen and activity levels and Clot lysis time 
analysis 
 TAFI Activity  TAFI Antigen Clot Lysis Time 
Materials 
required 
• 1x96	well	microtest	plate	
• 1	vial	TAFIa	Standard	
• 20ml	assay	buffer	
• 1	vial	TAFI	Developer	
• 1	vial	TAFI	Activation	Reagent	
• 1	vial	TAFI	Stop	Reagent	
• I	vial	Activation	enhancer	
• 0.22	 µm	 filtered	 deionised	water	
• 8	channel	pipette	(50-200µL)	
• 1	channel	pipette	(10-200µL)	
• 1.5	ml	microfuge	tubes	
• Microwell	plate	orbital	shaker	
• Microwell	plate	reader	set	at	a	wavelength	of	490nm	
• 2M	Sulphuric	acid	
 
• Micro	ELISA	plate	
• 100ml	F-Sample	dilutent	
• 3	 vials	 of	 Plasma	 TAFI	calibrator	 (normal	 plasma	calibrated	 with	 a	 reference	pool)	
• 1	vial	TAFI	Control	I	
• 1	vial	of	TAFI	Control	II	
• 3	 vials	 Anti-(H)-TAFI-HRP	immunoconjugate	
• 25ml	conjugate	diluent	
• 50	ml	washing	solution	
• 25ml	 3,3’,5,5’	Tetramethylbenzidine	
• 0.45M	Sulphuric	acid	
• 8	channel	pipette	(50-300µL)	
• 1	channel	pipette	(0-1000µL)	
• Micro	 ELISA	 washing	equipment	and	shaker	
• Micro	ELISA	plate	reader	(set	up	to	read	at	450	nm)	
 
• Innovin	(0.6	picoM)	
• 1M	Calcium	chloride	
• Phospholipid	buffer	
• tPA	[1680ng/ml]	
• Potato	 tuber	caboxypeptidase	inhibitor	(PTCI)[25µg/ml]	
• HEPES	 Buffer	(25mM	 ,	2.98g/500ml)	
• 20%	BSA	
• Flat	bottomed	NUNC	plates	
Expected 
range 
12-20µg/ml	 40-250%  
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There is a great deal of heterogeneity amongst the current literature, with some studies 
reporting TAFI antigen and others TAFI activity and CLT.  This has led to conflicting 
data being reported.  In order to grain a broader perspective of changes in TAFI during 
pregnancy all three methods were used in the following studies.    Not only does this 
allow comparison with available published data, it enables investigators to determine if 
changes in TAFI activity differ from those of antigen levels.  This may contribute to 
the understanding of various pregnancy related pathology including PET.   
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Chapter 4 
 
Changes in TAFI in uncomplicated pregnancy
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4.1 INTRODUCTION: 
There are marked changes in coagulation parameters in normal pregnancy (Franchini 
2006).  Many pro-coagulant factors increase during pregnancy creating a pro-
thrombotic state (Kadir R 2009; Huq FY 2011).  This is most likely a physiological 
attempt to limit bleeding after delivery.  Szecsi et al recently established reference 
ranges for coagulation factors in pregnancy and the puerperium (Szecsi PB 2010).  They 
reported: significantly increased levels of fibrinogen Factors VII, VIII, and IX; 
unchanged levels of factors II, V, X, XI, XII, protein C and antithrombin and decreased 
levels of protein S (Szecsi PB 2010).  However, TAFI was not included in the study 
(Szecsi PB 2010).   
 
Changes in TAFI levels during pregnancy have previously been studied.  However, 
reports in the literature are contradictory (Chabloz, Reber et al. 2001; Mousa, Downey 
et al. 2004; Watanabe, Minakami et al. 2004).   
 
This study aims to determine the nature of changes in TAFI in normal pregnancy and 
create pregnancy specific reference intervals TAFI Ag and TAFIa.   
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4.2 MATERIALS AND METHODS: 
 
4.2.1 Study design: 
This was a prospective longitudinal study of 130 women who attended the Obstetric 
units of two hospitals (Royal Free Hospital and Colchester General Hospital).  Written 
informed consented to participate in the study was obtained from all subjects.  Women 
were recruited from antenatal clinic.  The study protocol was reviewed and approved 
by the Royal Free Hospital Ethics committee (see appendix 1).  
 
4.2.2 Sample size: 
The sample numbers were chosen in line with the International Federation of Clinical 
Chemistry’s (IFCC) recommendation that a minimum sample size of 120 participants 
be used to calculate the reference range for a parameter (Institute 2008).   
 
4.2.3 Inclusion and Exclusion criteria: 
Only women with an uncomplicated singleton pregnancy were approached.  Women 
with a known history of: thrombophilia; thromboembolic disease; systemic lupus 
erythematosus; recurrent miscarriage; antiphospholipid syndrome; diabetes mellitus; 
hypertension; acute or chronic renal failure or other significant medical co-morbidity 
were excluded from the study.  The participants’ maternity records were reviewed after 
their deliveries.  Any participant who developed a complication (e.g. a hypertensive 
disorder of pregnancy, IUGR, venous thrombolic disease or pre-term delivery) during 
their pregnancy was excluded.  None of the participants were receiving non-steroidal 
anti inflammatory, anti-platelet or anticoagulant therapy.   
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4.2.4 Data collection:  
The following demographic data was collected prospectively for all study subjects: 
maternal age; parity; blood pressure and weight at antenatal booking visit (conducted 
by ten weeks gestation) and smoking history.   
 
Pregnancy gestation was calculated using the dating scan performed between 11-13+6 
weeks.  This scan is offered to all women receiving antenatal care in the UK, and 
determines the expected date of delivery using crown rump length.  Samples were 
collected from the participants in each trimester of pregnancy (first trimester samples 
between 0 and 12 weeks; second trimester between 13 and 28 weeks and the third 
trimester between 29 and 42 weeks).   
    
 
4.2.5 Blood collection 
Venous whole blood samples were collected for each of the 130 participants in the first, 
second and third trimesters of pregnancy.  Sample collection was performed in the 
sitting position by direct venepuncture and collected into citrated tubes.  Plasma 
samples were then prepared from citrated whole blood centrifuged at 2500g for 20 
minutes, divided into aliquots and frozen at -70° C until analysis.  Samples obtained at 
Colchester General Hospital were centrifuged and divided into aliquots on site and then 
transported to the Royal Free Hospital Haemophilia Centre laboratory for analysis.  
TAFI antigen (TAFI Ag), TAFI activity (TAFIa) and clot lysis time (CLT) assays were 
then performed. 
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4.2.6 Laboratory Method 
The following assays were performed on each collected sample: TAFI Ag levels, 
TAFIa and CLT in the presence of a buffer solution and CLT with PTCI (a TAI 
inhibitor).  All analysis were performed as described in chapter 3. 
 
4.2.7 Statistics 
Descriptive statistics were utilised for demographic data.  Continuous data were 
presented as mean and standard deviation.  Statistical analysis was performed using the 
Statistical Package for Social Sciences (SPSS) software (SPSS Inc. Released 2009. 
PASW Statistics for windows, Version 18.0. Chicago:SPSS Inc).   
In order to determine if the collected data had a normal distribution both visual and 
statistical methods were employed.  A histogram created using SPSS demonstrated that 
the data was not normally distributed.  This was then confirmed using the Shapiro-Wilk 
test in SPSS.  Both methods demonstrated that the data did not have a normal 
distribution, hence non-parametric tests were used in the analysis.  Comparisons 
between trimesters were performed using the Wilcoxon rank test.    Spearman 
correlation was used for correlation analysis.  A p value of <0.05 was accepted as 
statistically significant.   
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4.3 RESULTS: 
4.3.1 Population and Demographic data: 
One hundred and thirty women were recruited to participate in this part of study. 
Seventy three samples were collected from Colchester General Hospital and fifty seven 
from the Royal Free Hospital.  Three women developed PET and thus excluded.  Three 
second trimester samples were thawed and unsuitable for analysis, and one subject 
transferred her care to an alternate hospital in her third trimester and was lost to follow 
up.     
 
 
Table 5: Number of Samples analysed in each trimester of normal pregnancy 
 Number of samples analysed  
 TAFI Ag  TAFIa  CLT 
Trimester 1 127 127 104 
Trimester 2 124 124 107 
Trimester 3 126 126 102 
 
 
 
The demographic data for the study participants is presented in table 5.  The median 
age and parity of the participants were 32 (range 18-43) years and 1 (range 0-4) 
respectively.   
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Table 6: Distribution of age, parity and booking weight and blood pressure in 
normal pregnancy 
 Participants (n=127) 
Parity: 
Unknown 
0 
1 
2 
3+ 
 
0 (0%) 
36 (28%) 
49(39%) 
38 (30%) 
4 (3%) 
Smoker 
Unknown 
Yes 
No 
 
6 (5%) 
7 (6%) 
114 (89%) 
Age (years): 
Median (range) 
 
32 (18-43) 
Booking weight (kg) 
Median (range) 
 
66 (48-125) 
Systolic Blood Pressure at booking (mmHg) 
Median (range) 
 
111 (94-132) 
Diastolic Blood Pressure at Booking 
(mmHg) 
Median (range) 
 
70 (54-86) 
 
 
4.3.2 Changes in TAFI Ag, TAFIa and CLT with gestation in normal pregnancy: 
The mean, median and reference ranges of TAFI Ag, TAFIa and CLT are determined 
and presented in table 6a, 7 and 8. 
Overall, TAFI Ag, TAFIa and CLT increased with gestation, with the highest levels/ 
longest times seen in the third trimester. (see Table 6a and 6b).   
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Table 7a: Mean TAFI Ag, TAFIa and CLT throughout pregnancy 
 Mean Median (range) 
TAFI Ag (%) Trimester 1 123.7 109.5 (56-318) 
TAFI Ag (%)  Trimester 2 143.5 136 (62-280) 
TAFI Ag (%) Trimester 3 153.6 153 (56-280) 
 
TAFIa  (mcg/ml) Trimester 1 25.5 25 (5.8-53) 
TAFIa (mcg/ml) Trimester 2 28 27.5 (10-59 
TAFIa (mcg/ml) Trimester 3 50.7 30 (9-70) 
 
CLT (min) Trimester 1 69.4 68 (39-180) 
CLT (min) Trimester 2 87.0 82 (39-240) 
CLT (min) Trimester 3 99.6 93 (12-240) 
 
 
TAFI Ag levels: 
Mean TAFI Ag levels increased with gestation with the highest levels seen in the third 
trimester.   
Median TAFI Ag levels progressively increased with gestation with the highest levels 
seen in the third trimester.   
There was a significant increase in mean TAFI Ag levels between the first and second 
and the first and third trimesters (p=0.005 and p=0.006 respectively).   Levels did not 
increase significantly between the second and third trimesters (p=0.190).   
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TAFIa levels: 
TAFIa mirrored TAFI Ag levels.  Mean TAFIa levels increased with gestation with the 
highest levels seen in the third trimester.   
Median TAFIa levels also increased with gestation with the highest levels seen in the 
third trimester.   
There was a statistically significant increase in mean TAFIa between the first and 
second and the first and third trimesters (p=0.0005, p=0.0005 respectively).  Again, no 
significant increase was seen between the second and third trimesters (p=0.125).   
 
CLT: 
CLT in the presence of a buffer solution increased significantly with gestation.  Mean 
CLT became longer with gestation and the longest times were seen in the third 
trimester. 
Median CLT progressively increased with the longest times seen in the third trimester.  
Significantly longer times were seen between the first and second, first and third and 
second and third trimesters (p=0.001, p=0.009 and p=2.5 x10-6 respectively).   
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Table 7b: Statistical significance of changes in the mean values of 
TAFI antigen, activity and clot lysis time between trimesters 
 
  
Significance of difference between means in: 
 
  
Trimesters 1 and 2 
 
Trimesters 1 and 3 
 
Trimesters 2 and 3 
 
TAFI Ag  
 
 
0.005* 
 
0.006* 
 
0.190 
 
TAFIa  
 
 
0.0005* 
 
0.0005* 
 
0.125 
 
CLT 
   
 
0.001* 
 
0.085* 
 
P<0.0001* 
*denotes statistical significance where p<0.05 
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Figure 4: Changes in Mean TAFI Ag levels throughout pregnancy 
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Figure 5 : Changes in Mean TAFIa  levels throughout pregnancy 
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Figure  6: Changes in Mean CLT throughout pregnancy 
 
 
 
 
  
	 96 
 
 
 
Figure 7: Changes in TAFI Ag with gestation 
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Figure 8: Changes in TAFIa with gestation 
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4.3.3: Reference ranges for TAFI in normal pregnancy: 
The reference intervals for TAFI Ag and TAFI a in each trimester are show in the table 
below. 
 
  
Table 8: Reference intervals of TAFI Ag and TAFIa during each trimester of 
normal pregnancy 
 
Reference 
Interval 
Lower 
Quartile 
Median 
(range) 
Upper 
Quartile 
Mean  Standard 
deviation 
TAFI Ag (%) 1st 
Trimester 
89.5 109.5 (56-318) 142 123.7 48.7 
TAFI Ag (%) 2nd 
Trimester 
110 136 (62-280) 168 143.5 49.2 
TAFI Ag (%) 3rd 
Trimester 
116 153 (56-280) 186 152.6 50.7 
TAFIa (mcg/ml) 
1st Trimester 
21 25 (5.8-53) 31 25.5 9.6 
TAFIa (mcg/ml) 
2nd Trimester 
22.4 27.5 (10-59) 34 28.0 10.1 
TAFIa (mcg/ml)  
3rd Trimester 
24.5 30 (9-70) 35 50.7 9.4 
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Table 9: Reference ranges of TAFI Ag and TAFIa in normal pregnancy in each 
trimester (Values are mean+/- SD (95% confidence intervals)) 
 
 
TAFI Ag (%) 1st Trimester 
 
123.7 +/- 48.7 (26.2-221.1) 
 
TAFI Ag  (%) 2nd Trimester 
 
143.5 +/- 49.2 (45.2-241.9) 
 
TAFI Ag (%)  3rd Trimester 
 
152.6 +/- 50.7 (51.3-254.0) 
 
 
TAFIa  (mcg/ml)1st Trimester 
 
25.5+/- 9.6 (6.4-44.7) 
 
TAFIa (mcg/ml)2nd Trimester 
 
28.0 +/- 10.1 (7.8-48.3) 
 
TAFIa (mcg/ml) 3rd Trimester 
 
29.8 +/- 9.4 (10.9-48.6) 
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Figure 9: Distribution of TAFIa in each trimester of normal pregnancy 
 
 
 
 
 
Figure 10: Distribution of TAFI Ag in each trimester of normal pregnancy 
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Figure 11: Distribution of CLT in each trimester of normal pregnancy 
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Figure 12: The distribution of TAFIa in the first trimester 
 
 
Figure 13: The distribution of TAFIa in the second trimester 
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Figure 14: The distribution of TAFIa in the third trimester 
 
 
 
 
 
Figure 15: The distribution of TAFI Ag in the first trimester 
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Figure 16: The distribution of TAFI Ag in the second trimester 
 
 
Figure 17: The distribution of TAFI Ag in the third trimester 
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4.3.4 CLT in the presence of Buffer and PTCI: 
 
The contribution of TAFI to the impairment of fibrinolysis was quantified by assessing 
the difference in CLT after the addition of a specific TAFIa inhibitor (PTCI).  CLT in 
the presence of PTCI was significantly shorter in all trimesters, confirming that TAFI’s 
contribution to the inhibition of fibrinolysis.   
 
 
 
Table 10: Contribution of TAFIa to fibrinolysis as assessed by the difference 
between CLT in the presence of buffer and the presence of PTCI in normal 
pregnancy  
 
 Median CLT in 
the presence of 
buffer (min) 
Median CLT in 
the presence of 
PTCI (min) 
P value for the 
difference between 
the medians* 
 
Trimester 1 
  
 
68 
 
51 
 
<0.001 
 
Trimester 2  
 
 
82 
 
66 
 
<0.001 
 
Trimester 3  
 
 
93 
 
72 
 
<0.001 
*Significance was assumed <0.05 using Wilcoxon sum rank test 
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4.3.5 Correlation between TAFI and CLT 
The correlation between CLT and TAFI Ag and TAFIa levels was also investigated.  
There was a general trend for longer CLT with higher levels of both TAFI Ag and 
TAFIa.  No significant positive correlation between CLT and TAFI Ag was seen at any 
gestation. 
 
Table 11: Correlation between TAFIag and TAFIa with CLT in each trimester 
 Pearson’s correlation r2 P value 
TAFIag and CLT in T1 0.170 0.229 
TAFIag and CLT in T2 0.030 0.833 
TAFIag and CLT in T3 -0.213 0.126 
   
TAFIa and CLT in T1 -0.050 0.730 
TAFIa and CLT in T2 -0.059 0.686 
TAFIa and CLT in T3 -0.213 0.756 
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Figure 18a: Correlation between TAFI Ag and CLT in the first trimester 
(r=0.170) 
  
Figure 18b : Correlation between TAFIa and CLT in the first trimester 
(r=0.050) 
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Figure 19a: Correlation between TAFI Ag and CLT in the second trimester 
(r=0.030) 
 
 
Figure 19b : Correlation between TAFIa and CLT in the second trimester  
(r= -0.059) 
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Figure 20a : Correlation between TAFIAg and CLT in the third trimester (r=-
0.213) 
 
 
 
Figure 20b: Correlation between TAFIa and CLT in the third trimester (r= -
0.044) 
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4.4 Discussion: 
The present study is unique amongst published data, in that it investigates the nature of 
changes in TAFI during pregnancy using TAFI Ag, TAFIa and CLT in a longitudinal 
manner.  Furthermore, it is the largest prospective longitudinal study to date including 
127 uncomplicated pregnancies and the first to provide a reference range for TAFI Ag 
and TAFIa.  We have demonstrated that TAFI levels increase with gestation with levels, 
plateauing in the third trimester.  There are significant increases in TAFI Ag, TAFIa 
and CLT between the first and second trimesters and the first and third trimesters.  A 
general trend for longer CLT was seen with higher levels of TAFI Ag and TAFIa.  In 
addition, the contribution of TAFI to the impairment of fibrinolysis was confirmed by 
significantly shorter CLT seen at every gestation when the assay was performed in the 
presence of PTCI 
 
There are contrasting reports of TAFI levels during pregnancy.  Three out of the four 
published studies considering TAFI Ag and TAFIa in normal pregnancy demonstrate a 
significant progressive increase from early pregnancy (Chabloz, Reber et al. 2001; 
Watanabe, Wada et al. 2001; Mousa, Downey et al. 2004).  Chabloz et al performed a 
cross sectional cohort study assessing TAFI Ag and D-dimer levels in 144 women with 
uncomplicated singleton pregnancies (Chabloz, Reber et al. 2001) and reported a steady 
significant increase in TAFI Ag levels between 10 and 25 weeks gestation, after which, 
TAFI Ag levels plateaued until they started to fall after delivery (Chabloz, Reber et al. 
2001).  These results support the findings of the current study that demonstrated a 
significant increase in TAFI Ag and TAFIa between the first and second trimesters.      
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A more recent cross-sectional case control study by Watanabe et al focused on changes 
in TAFIa during pregnancy (Watanabe, Wada et al. 2001).  This prospective study 
demonstrated significantly higher TAFIa in 176 women with normal pregnancies 
compared to 15 non-pregnant women and confirmed a progressive increase in TAFIa 
starting in the first trimester, continuing up to 20 weeks after which levels remained 
steady until they started to decrease postnatally (Watanabe, Wada et al. 2001).  This is 
one of the few studies that examines TAFI activity in normal pregnancy (Watanabe, 
Wada et al. 2001).  However, it was cross-sectional in design, whereas in the current 
study is longitudinal, examining the changes in TAFI Ag and TAFIa in 130 women in 
each trimester of their pregnancies.   
 
Another cross sectional study of 183 normal pregnancies measured TAFI Ag levels at 
four weekly intervals and reported a progressive increase in TAFI Ag throughout 
pregnancy, maximal at 35-39 weeks gestation, and a gradual decline in the levels post 
delivery (Mousa, Downey et al. 2004).  Although it did not report changes in TAFIa, 
this study did examine TAFI’s functional effect by measuring CLT, both with and 
without the addition of a TAFI inhibitor.   The changes in CLT mirrored those of TAFI 
Ag, increasing with gestation.  Thus, there is a progressive impairment of fibrinolysis 
as pregnancy progresses.  Addition of the TAFI inhibitor during the CLT assay 
abrogated the increase in CLT, suggesting that the decreased rate of fibrinolysis is 
attributable to TAFI (Mousa, Downey et al. 2004).  Once more, these results support 
the findings of the current study that show that CLT progressively increases during 
pregnancy and that there is a degree of correlation between CLT and TAFI Ag.   
 
	 112 
Many previous studies have used assays that were inadequately validated, making 
interpretation of their results difficult.  Thus, accurate comparison of data generated by 
different studies will not be possible until an international standard for TAFI Ag is 
defined.  In this study, to overcome the difficulties resulting from each of the various 
assays, all three were performed on each sample giving a much clearer picture of 
changes in TAFI during pregnancy. 
 
Although samples were collected from two different hospital sites, efforts were made 
to minimise heterogeneity between the methods by which the samples were prepared 
for analysis.  The samples collected at Colchester General Hospital were spun on site 
and separated into individual aliquots before they were transported to the Royal Free 
Hospital for analysis.  This ensured that all samples were prepared in the same manner 
before their analysis at the Royal Free Hospital.   
 
This study does have certain limitations. As this study does not include non-pregnant 
levels from the participants, it cannot confirm that TAFI Ag, TAFIa and CLT are raised 
in the first trimester or describe changes in TAFI post-partum 
 
In conclusion, the data from this study provides reference ranges to TAFI Ag and 
TAFIa levels for the three trimesters of pregnancy.  The study findings also supports 
previous reports of TAFI Ag, TAFIa and CLT increasing with gestation in normal 
pregnancy, with a significant in crease in TAFI Ag and TAFIa levels between the first 
and second and first and third trimesters.  Levels progressively increased throughout 
pregnancy.  There was no significant change in TAFI Ag or TAFIa levels between the 
second and third trimesters, confirming the results of previous cross sectional studies.  
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It confirms the contribution of TAFI to the impairment of fibrinolysis as CLT in the 
presence of a specific TAFI inhibitor (PTCI) were significantly shorter at all gestations.  
This information can be used when examining the role of TAFI in pregnancy related 
complications, to elaborate on the pathogenisis of conditions such as PET.   
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Chapter 5  
THROMBIN ACTIVATABLE FIBRINOLYSIS 
INHIBITOR IN PRE ECLAMPSIA 
	 115 
5.1 Introduction: 
As discussed in chapter 2, PET is characterised by impaired placental circulation and 
has been associated with impaired fibrinolysis (Perry and Martin 1992; Gilabert, 
Estelles et al. 1995; Schjetlein, Haugen et al. 1997; Sheppard and Bonnar 1999).  Thus, 
TAFI may be involved in the abnormal haemostasis seen in women with PET.   
This study aims to compare TAFI levels in women with PET to the reference ranges 
created in the previous chapter to evaluate TAFI’s contribution to the pathophysiology 
of PET.   
 
5.2 METHODS AND MATERIALS: 
5.2.1 Study design: 
This was a prospective cohort study of women who attended the Obstetric units of two 
hospitals (Royal Free Hospital and Colchester General Hospital).  Two sample 
populations were included.  The control group were the previously described in Chapter 
4: a cohort of 127 women with uncomplicated singleton pregnancies from whom 
samples were collected in each trimester of their pregnancy. The study protocol was 
reviewed and approved by the Royal Free Hospital Ethics committee (see appendix1).   
The case cohort consisted of 46 women diagnosed with PET (18 women from 
Colchester General hospital and 28 from the Royal Free Hospital).  These women were 
recruited from antenatal clinic, the maternity Day Assessment Unit or labour ward after 
a diagnosis of PET had been confirmed. Thirty-six women were diagnosed with PET 
in the third trimester, and nine in the second trimester.  Of the nine women diagnosed 
in the second trimester, only three remained pregnant after 28 weeks gestation.  
Samples were collected in both the second and third trimesters of women who 
	 116 
developed PET before 28 weeks and remained pregnant in the third trimester.  Written 
informed consented was obtained from all patients and controls.   
 
5.2.2 Inclusion and Exclusion criteria: 
PET was defined as gestational hypertension of at least 140/90 mmHg on two separate 
occasions at least ≥4 hours apart associated with significant proteinuria of at least 
300mg in a 24-hour urine collection.  Only women with a singleton pregnancy were 
approached.  Women with a pre-pregnancy history of: thrombophilia; thromboembolic 
disease; systemic lupus erythematosus; recurrent miscarriage; antiphospholipid 
syndrome; diabetes mellitus; hypertension; acute or chronic renal failure or other 
significant medical co-morbidity were excluded from the study.  None of the 
participants were receiving non-steroidal anti inflammatory, anti-platelet or 
anticoagulant therapy at the time of sample collection.   
 
5.2.3 Data collection:  
The following demographic data was collected prospectively for all study subjects: 
maternal age; parity; blood pressure and weight at antenatal booking visit and smoking 
history.   
Pregnancy gestation was calculated using the dating scan performed between 11-13+6 
weeks.      
 
5.2.4 Blood collection 
Sample collection was performed in the sitting position by direct venepuncture and 
collected into citrated tubes.  Plasma samples were then prepared from citrated whole 
blood centrifuged at 2500g for 20 minutes, divided into aliquots and frozen at -70° C 
	 117 
until analysis.  Samples obtained at Colchester General Hospital were centrifuged and 
divided into aliquots prior to being transported to the Royal Free Hospital Haemophilia 
Centre laboratory for analysis.  TAFI antigen (TAFI Ag), TAFI activity (TAFIa) and 
clot lysis time (CLT) assays were then performed. 
 
5.2.5 Laboratory Method 
Each collected sample was used to determine TAFI Ag, TAFIa and CLT with and 
without the addition of PTCI.  Analysis of the samples was performed as previously 
described in chapter 4. TAFI Actichrome®, TAFI Antigen Concentration (ELISA) and 
Clot lysis time were employed to determine TAFIa, TAFI Ag and CLT respectively.   
 
5.2.6 Statistics 
Descriptive statistics were utilised for demographic data.  Continuous data were 
presented as mean and standard deviation.  Statistical analysis was performed using the 
Statistical Package for Social Sciences (SPSS) software (SPSS Inc. Released 2009. 
PASW Statistics for windows, Version 18.0. Chicago:SPSS Inc).   
In order to determine if the collected data had a normal distribution both visual and 
statistical methods were employed.  A histogram created using SPSS demonstrated that 
the data was not normally distributed.  This was then confirmed using the Shapiro-Wilk 
test in SPSS.  Both methods demonstrated that the data did not have a normal 
distribution, hence non-parametric tests were used in the analysis.  Comparisons 
between trimesters were performed using the Wilcoxon rank test.    Spearman 
correlation was used for correlation analysis.  A p value of <0.05 was accepted as 
statistically significant.   
5.3 RESULTS: 
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Forty-three women were recruited to participate in the PET arm of the study.  A further 
three women who were originally recruited to as part of the control group developed 
PET in the third trimester.  Their results were included in the PET group.  The numbers 
of samples collected in each trimester for the PET group are described in the table 
below. 
 
 Table 12: Number of women  with PET recruited in each trimester  
 
Trimesters in which samples collected  
 
Number of women from whom samples 
collected (total n=48) 
 
Trimesters 1, 2 and 3 
 
3 
 
Trimesters 2 and 3 
 
3 
 
Trimester 2 only (delivery prior to 28 
weeks) 
 
6 
 
Trimester 3 (PET diagnosed after 28 weeks) 
 
36 
 
 
5.3.1 Demographic data: 
The demographic data for the study participants is presented in table 12.  The median 
age and parity of the participants were 28 (range=18-40) years and 0 (range 0-4) 
respectively.   
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Table 13: Distribution of age, parity and booking weight and blood pressure in 
women with PET 
 Participants (n=46) 
Parity: 
Unknown 
0 
1 
2 
3+ 
 
0 (0 %) 
36 (78 %) 
6 (13%) 
3 (7%) 
1 (2%) 
Smoker 
Unknown 
Yes 
No 
 
0 (0 %) 
2 (4 %) 
44 (96 %) 
Age (years): 
Median (range) 
 
28 (18-40) 
Booking weight (kg) 
Median (range) 
 
74.5 (46-110) 
Systolic Blood Pressure at booking (mmHg) 
Median (range) 
 
118 (90-138) 
Diastolic Blood Pressure at Booking 
(mmHg) 
Median (range) 
 
76 (60-98) 
 
 
5.3.2 Changes in mean levels in the PET group: 
TAFI Ag: 
Mean TAFI Ag levels increased between the first and second trimesters and then 
dropped between the second and third.  This was mirrored by the changes in Median 
TAFI Ag levels in women with PET- levels increased between the first and second 
trimesters and fell between the second and third trimesters.   
Mean TAFI Ag levels were lower in the third trimester than the second trimester.  
However, this change was not statistically significant (p=0.25).  
TAFIa: 
Mean TAFIa increased with gestation with the highest levels seen in the third trimester.   
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Median TAFIa levels also increased with gestation with the highest levels seen in the 
third trimester. 
The change in mean TAFIa with between the second and third trimester was not 
statistically significant (p=0.24).   
CLT: 
Both mean and median CLT increased with gestation with the longest times seen in the 
third trimester.   
The increase in mean CLT between the second and third trimesters achieved statistical 
significance (p=0.039).   
 
Table 14a: Changes in TAFI Ag, TAFIa and CLT in women with PET 
 Mean Median (range) 
TAFI Ag  (%) Trimester 1 132.3 131 (100-161) 
TAFI Ag  (%) Trimester 2 198.0 204 (96-244) 
TAFI Ag  (%) Trimester 3 176.2 164 (74-280) 
 
TAFIa  (mcg/ml) Trimester 1 19.5 19.5 (18-21) 
TAFIa (mcg/ml) Trimester 2 24.4 24 (14-38) 
TAFIa  (mcg/ml)Trimester 3 28.2 26 (7-61) 
 
CLT (min) Trimester 1 67 67 (66-68) 
CLT (min) Trimester 2 74.6 82 (45-97) 
CLT (min) Trimester 3 118.2 120 (65-240) 
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Table 14b: Statistical significance of changes in the mean values of TAFI 
antigen, activity and clot lysis time between trimesters 
 
 
 Significance of difference between means in 
Trimesters 2 and 3 
TAFI Antigen in PET group 0.25 
TAFI activity in PET group 0.24 
CLT in PET group 0.039* 
 
*denotes statistical significance where p<0.05 
 
Figure 21: The distribution of TAFI Ag in the second and third trimesters in 
PET 
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Figure 22: The distribution of TAFIa in the second and third trimesters in PET 
 
 
 
Figure 23: The distribution of  CLT in the second and third trimesters in PET 
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5.3.3 Comparison of PET and normal pregnant controls: 
TAFI Ag: 
Mean TAFI Ag levels were significantly higher in the PET group when compared with 
normal pregnancy in the second and third trimesters (p=0.002 and p=0.012 
respectively).   
TAFIa: 
Mean TAFIa levels were not found to be significantly different in the PET group when 
compared with the normal pregnant population (p=0.25 and p=0.29 in the second and 
third trimesters respectively).   
CLT: 
Mean CLT in the third trimester was not significantly higher in the PET group than in 
normal pregnancy (p=0.055).  Additionally, there was no significant difference in CLT 
between the PET group and normal pregnant population seen in the second trimester 
(p=0.376).  
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Table 15: Comparison of Mean TAFI Ag, TAFIa and CLT in PET group and 
normal pregnant controls 
 
 Mean in PET  Mean in Normal 
Pregnancy 
P value for the 
difference between 
means* 
TAFIag 2nd 
Trimester 
198.0 143.5 0.002* 
TAFIag 3rd Trimester 176.2 152.7 0.012* 
 
TAFIa 2nd Trimester 24.4 28.0 0.265 
TAFIa 3rd Trimester 28.2 29.8 0.344 
 
CLT 2nd Trimester 74.6 87.02 0.376 
CLT 3rd Trimester 118.2 99.6 0.055 
*Calculated using independent samples t-test 
 
Three women who were initially recruited into the control group developed PET.  Their 
results are displayed in the graphs below.   
There was a trend for higher mean levels of TAFI Ag; lower TAFIa levels and longer 
CLTs in this small sample of women when compared with the control group.   
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Figure 24a: Mean TAFI Ag in each trimester in women with PET 
 
 
 
Figure 24b: Mean TAFIa in each trimester in women with PET 
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Figure 24c: Mean CLT in each trimester in women with PET 
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5.3.4 CLT in the presence of Buffer and PTCI: 
 
The contribution of TAFI to the impairment of fibrinolysis was quantified by assessing 
the difference in CLT after the addition of a specific TAFIa inhibitor (PTCI).  CLT in 
the presence of PTCI was significantly shorter in all samples in both the control and 
PET groups.   
 
 
 
 
Table 16: Contribution of TAFIa to fibrinolysis as assessed by the difference 
between CLT in the presence of buffer and the presence of PTCI in normal 
pregnancy and PET 
 
 Median CLT in the 
presence of buffer 
(min) 
Median CLT in the 
presence of PTCI 
(min) 
P value for the 
difference between 
the medians* 
Trimester 2 PET 
group 
82 67.5 <0.001 
Trimester 3 PET 
group 
120 94 <0.001 
*Significance was assumed <0.05 using Wilcoxon sum rank test 
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5.3.5 Correlation between TAFI and CLT in PET 
 
The correlation between CLT and TAFI Ag and TAFIa levels was also investigated.  
There was a general trend for longer CLT with higher levels of both TAFI Ag and 
TAFIa.  No significant correlation between CLT and TAFI Ag or TAFIa was seen at 
any gestation. 
 
 
 
Table 17: Correlation between TAFIag and TAFIa with CLT in each trimester 
 
 Pearson’s correlation r2 P value 
TAFIag and CLT in T2 -0.967 0.833 
TAFIag and CLT in T3 -0.137 0.126 
   
TAFIa and CLT in T2 0.103 0.686 
TAFIa and CLT in T3 0.137 0.756 
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Figure 25: Correlation between TAFI Ag and CLT in the third trimester in 
women with PET(r=0.137) 
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Figure 26: Correlation of TAFIa and CLT in the third trimester in women with 
PET (r=0.137) 
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5.4 DISCUSSION: 
In the current study, significantly higher TAFI Ag levels were seen in the pre-eclamptic 
population.  Additionally, TAFI Ag levels were higher in the second trimester than the 
third.  This suggests that the impaired fibrinolysis seen in pre-eclamptic women may 
be attributed to higher TAFI Ag levels.   
 
The clinical manifestations of PET can occur long after the abnormal placentation that 
precedes systemic endothelial dysfunction.  This has led to the disease being described 
as a two stage disorder (Borzychowski AM 2006).   Severe PET is more likely to present 
at an earlier gestation.  We propose that the trend for higher TAFI Ag levels in the 
second trimester may contribute to further impairment of fibrinolysis, resulting in more 
severe disease, presenting earlier in pregnancy.  We suggest that the lower TAFIa 
demonstrated in the PET group can be accounted for by the increased consumption of 
TAFI.   
 
No significant difference was demonstrated between CLTs in the pre-eclamptic and 
general pregnant populations.  This may be attributed to several factors: firstly, the 
small sample size of pre-eclamptic women in the second trimester (n=12).  Secondly, 
the increased levels of TAFI Ag, lower levels of TAFa and shorter CLT seen in the 
second trimester in the PET group may be a result of more severe disease presenting at 
earlier gestations. TAFI Ag ELISA assays also quantify inactivated TAFIa.  Thus, 
increased consumption of TAFIa leads to a corresponding shorter CLT and increased 
quantities of inactivated TAFIa fragments resulting in a higher measured TAFI Ag 
level.   
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The contribution of TAFI to the impairment of fibrinolysis in pre-eclamptic women is 
confirmed by the fact that CLTs in the presence of a TAFI inhibitor were significantly 
shorter than those performed with a buffer.   
 
There are conflicting reports of TAFI Ag levels in pre-eclamptic women in the literature 
(Antovic, Rafik Hamad et al. 2002; Alacacioglu, Ozcan et al. 2004; Zhang, Hu et al. 
2008; Martinez-Zamora, Tassies et al. 2010).  Two of the four studies of TAFI Ag 
levels in women with PET compared to normal pregnant controls demonstrated higher 
levels in the PET group (Alacacioglu, Ozcan et al. 2004; Zhang, Hu et al. 2008).  This 
supports the findings of the current study.   
Antovic et al measured third trimester TAFI Ag levels in 46 women with PET (Antovic, 
Rafik Hamad et al. 2002) and reported significantly lower levels in PET compared to 
normal controls.  The majority (63%) of their study population was composed of 
women with severe PET, which may account for the discordance with the results of the 
current study.  The majority of our sample population had mild PET.  Antovic et al 
attributed their findings to the impaired liver function and urinary excretion seen in 
women with severe PET.   
 
This study does have limitations.  Women were only recruited into the PET group after 
a diagnosis of PET had been confirmed.  Thus, it was not possible to ascertain if higher 
levels of TAFI Ag seen in the PET group ante cede the manifestation of clinical 
symptoms.  A large multicentre, longitudinal study would be able to collect this data.  
Furthermore, the PET group had a very small sample size of only three women.  Thus, 
it does not provide enough data to compare early onset PET to late onset PET.  It may 
be that severe, early onset PET has a different pathophysiology to PET at late 
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gestations.  Finally, the current study assesses markers in the peripheral circulation and 
therefore does not evaluate haemostasis in the uteroplacental unit.   
In conclusion, this is the only study to date that overcomes the various disadvantages 
of the different methodologies of quantifying TAFI by using multiple assays.  The role 
of TAFI in the pathogenesis of PET could be confirmed by larger studies using the 
same methodology.   
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Chapter 6 
 
OVERALL CONCLUSIONS AND 
SUGGESTIONS FOR FUTURE RESEARCH 
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6.1.1 Overall Conclusions: 
This thesis includes the largest longitudinal study of TAFI in normal pregnancy.  In 
addition it has provided pregnancy specific reference ranges for TAFI Ag and TAFIa.  
Both TAFI Ag and TAFIa levels were seen to increase with gestation with significant 
increases between levels in the first and second and first and third trimesters.  TAFI’s 
contribution to the impaired fibrinolysis characteristic of pregnancy was confirmed by 
significantly shorter CLTs after the addition of a specific TAFI inhibitor at all 
gestations.  By quantifying both TAFI Ag and TAFIa levels and TAFI’s contribution 
to altered haemostasis in pregnancy using CLT with and without PTCI, this study 
overcomes the difficulties introduced by the individual methods of measuring TAFI. 
By generating a pregnancy specific reference range for TAFI, this study provides the 
basis for larger studies examining the role of TAFI in complications of pregnancy, 
including recurrent miscarriage, hypertensive disorders and IUGR.   
 
Significantly higher levels of TAFI Ag were demonstrated in pre-eclamptic women 
compared with the normal pregnant population.  A trend for lower TAFIa levels in the 
PET group was also demonstrated.  We propose that in addition to having a greater 
amount of TAFI Ag, a larger proportion of activated TAFI is consumed in the pre-
eclamptic state leading to lower levels of fibrinolysis.  This was supported by a trend 
for longer CLT seen in the PET group compared to normal controls.  The findings of 
this study suggest that anti TAFI agents may have a role in the treatment or prevention 
of PET.   
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6.2 Suggestions for Future Studies 
A larger multicentre prospective longitudinal study would be able to capture a large 
enough sample size to determine if raised TAFI Ag precedes the onset of clinical 
manifestations of PET.  A sample size of approximately 1250 women would be required 
to capture data from 100 pre-eclamptic women.  If TAFI Ag levels are raised in the first 
trimester it has the potential to be used as a screening test for PET, allowing for 
increased surveillance and early treatment in high-risk populations, leading to reduced 
maternal and fetal morbidity and mortality.   
 
As described in previous chapters, the pathophysiology of PET has been studied 
extensively and as yet, remains undetermined.  It is likely that PET has a multifactorial 
pathogenesis and that altered haemostasis is not the only mechanism at work.   
Therefore, patients at high risk of PET may be better identified using a combination of 
multiple predictors including uterine artery Doppler studies and other biomarkers for 
PET.  This approach has been used successfully to screen for Down’s syndrome and 
other trisomies in early pregnancy.    
 
A woman’s risk of developing PET can be classified using several different methods 
including: ultrasound; molecular markers in the maternal circulation; clinical history 
and booking blood pressure.  Abnormal waveforms in the uterine artery Dopplers, 
demonstrated by a pulsitility index over the 95th centile and/ or notching predicts PET 
in high risk populations.  Abnormal uterine artery Dopplers can identify 40% of women 
who go on to develop PET (Papageorghiou AT 2002).  Maternal history at booking 
assessing for risk factors such as Afro-Caribbean race, a high body mass index, a 
personal or family history of PET (especially if early onset or severe disease) has been 
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shown to predict 47% of cases of PET and 35% of pregnancies affected by gestational 
hypertension (Poon LC 2010).  The combination of maternal history and uterine artery 
Dopplers at 23 weeks gestation predict PET in 67.5% of women (Papergeorghiou AT 
2005).  However, due to a false positive rate of 25%, this model of prediction is of little 
value clinically (Papergeorghiou AT 2005).  A large number of potential vascular 
biomarkers have been investigated as potential non-invasive methods of predicting 
PET.  The most promising candidate molecular markers for pre-symptomatic PET 
include: inhibin A, PLGF, s-Flt 1, sEnd, VEGF and PAPP-A (Mone F 2014).    
Akolekar et al recently described a model to predict PET using maternal characteristics, 
uterine artery Doppler pulsitility index, mean arterial pressure and biomarkers (serum 
pregnancy associated plasma protein and placental growth factor).  Their study 
demonstrated a linear correlation between the components of their model and gestation 
age at delivery in women with PET that was able to predict 54% of all cases of PET 
(Akelokar R 2013).  TAFI may prove to be part of a larger model to screen for PET in 
early pregnancy.  A large statistical model of demographics, biomarkers including first 
trimester TAFI levels in conjunction with ultrasound parameters could form a robust 
screening method to predict the severity and onset of PET.  
 
At present, all women in the UK are screened at booking for risk factors for PET, still 
birth and intrauterine growth restriction and PAPP-A is part of the combined screening 
test for chromosomal abnormalities.    Women who are deemed to be at high risk of 
pregnancy complications due to placental insufficiency are then referred for uterine 
artery dopplers in the second trimester.  Further studies could use the available 
screening tests that are part of routine antenatal care.  Thus the combination of TAFIa 
and TAFI Ag levels in the second trimester with maternal history, uterine artery 
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dopplers and PAPP-A, may prove an effective screening test for the development of 
PET which has a higher specificity than the methods currently available.   
However, even if the above model proved to be highly sensitive and specific, it may 
not prove cost effective.  The cost of TAFI Ag and TAFIa assays used in this thesis 
were £7.00 and £12.00 per participant respectively.  The laboratory time and technician 
costs would also have to be considered.  Each TAFIa and TAFI Ag assay took 
approximately four to five hours to perform.  In addition, each kit would require 
calibration prior to its use.  Factoring in all of these issues, producing a TAFIa and 
TAFI Ag level for a single patient would cost approximately £90.   
 
EF6265 is a synthetic highly specific inhibitor of TAFIa that does not affect plasmin, 
thrombin or any other serine proteases (Muto Y 2009).  Toxicological studies have 
demonstrated EF6265 as having an acceptable safety profile to be used as an injectable 
agent (Muto Y 2009).  EF6265 has been used to determine TAFIa’s role in sepsis.  
Animal studies show that post treatment with EF6265 there are decreased markers of 
end organ damage in endotoxic septic shock (Muto Y 2009).  High dose antithrombin 
treatment improves clinical outcomes in patients with sepsis omplicated with 
disseminated intravascular coagulation (DIC) in the critical care setting (Warren BL 
2001).  Specific TAFIa inhibitors would increase the pro-fibrinolytic response due to 
DIC without decreasing the amount of fibrin that could act as a co-factor for tPA 
mediated plasminogen activation.  Additionally, the thrombin induced release of tPA 
would be maintained.  This data could be extrapolated to the pre-eclamptic population 
and may improve outcomes in women with severe PET who develop DIC.  EF6265 
could be used to study the effects of TAFIa inhibition in hypertensive disorders of 
pregnancy.   
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TAFI may also have a role in the pathophysiology of other complications of pregnancy 
including intrauterine growth retardation, recurrent miscarriage and implantation 
failure after embryo transfer. There are contradictory reports of TAFI levels in 
reproductive failure (Folkeringa, Korteweg et al. 2009; Knol, Veeger et al. 2009; 
Masini, Ticconi et al. 2009; Martinez-Zamora, Creus et al. 2010; Pruner, Djordjevic et 
al. 2010; Legnani, Bovara et al. 2012).  A sufficiently powered cross sectional study 
could compare TAFI levels in women with a history of recurrent miscarriage or 
recurrent implantation failure with women who had successfully carried uncomplicated 
pregnancies to term.  If women with recurrent pregnancy loss have altered TAFI levels, 
TAFI inhibitors may have a role in the prevention of miscarriage and improve the 
outcome of assisted reproductive techniques. 
 
The findings presented in this thesis contribute to the understanding of the origins of 
PET and provide a basis for the further work to predict the onset and severity of the 
disease as well as other obstetric complications that are attributed to disordered 
haemostasis.   
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